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  1 
1 Summary 
 
Adoptive transfer of T cell receptor (TCR)-engineered T cells is a promising approach in cancer 
therapy but needs improvement for effective treatment of solid tumours. So far clinical 
approaches have focussed on CD8 T cells because of their cytotoxic function. However, the 
importance of CD4 T cells to induce tumour regression by giving essential help to CD8 T cells or 
by their own means has become apparent and suggests the use of CD4 T cells in adoptive T cell 
therapy. Regarding the development of TCRs for use in CD4 T cells, it is unclear, whether the 
human CD4 T cell repertoire against shared (self) tumour antigens has been shaped by tolerance 
mechanisms and lacks highly functional TCRs suitable for therapy. The aim of this study was to 
generate optimal-affinity major histocompatibility class II (MHC II)-restricted TCRs against the 
tumour-associated antigen NY-ESO and investigate whether such TCRs can be generated from 
the human TCR repertoire. TCRs were isolated from CD4 T cells of a human donor representing 
an antigen-positive host as well as from transgenic mice that express a diverse human TCR 
repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-negative, thus serving as 
antigen-negative and therefore non-tolerant source for TCRs. NY-ESO-reactive TCRs from the 
mice showed superior recognition of tumour cells and higher peptide sensitivity compared to 
TCRs from humans. We identified a candidate TCR, TCR-3598_2, which, transduced in CD4 T 
cells, caused tumour regression in combination with NY-ESO-redirected CD8 T cells in a mouse 
model of adoptive T cell therapy. A clinical version of TCR-3598_2 was tested for functionality 
in preparation of a clinical trial. These data suggest that MHC II-restricted TCRs against NY-
ESO from humanized non-tolerant mice are of optimal affinity unlike human-derived TCRs and 
that the combined use of MHC I- and II-restricted TCRs against NY-ESO can make adoptive T 










Der adoptive Transfer von T-Zell-Rezeptor (TZR)-veränderten T-Zellen ist ein 
vielversprechender Ansatz in der Krebstherapie, muss jedoch für eine effektive Behandlung von 
soliden Tumoren verbessert werden. Bisher haben sich klinische Ansätze aufgrund der 
zytotoxischen Funktion auf CD8-T-Zellen konzentriert. Die Bedeutung von CD4-T-Zellen für die 
Tumorabstoßung durch T-Zellhilfe für CD8-T-Zellen sowie durch eigene 
Zerstörungsmechanismen ist jedoch deutlich geworden und legt den Einsatz von CD4-T-Zellen in 
der adoptiven T-Zelltherapie nahe. Hinsichtlich der Entwicklung von therapeutischen TZRs für 
CD4-T-Zellen ist unklar, ob das menschliche CD4-T-Zellrepertoire gegen tumorassoziierte 
(Selbst-) Antigene durch Toleranzmechanismen geprägt ist und keine hochfunktionellen 
Therapie-geeigneten TZRs aufweist. Ziel dieser Studie war, Haupthistokompatibilitätskomplex 
(MHC) II-restringierte TZRs mit optimaler Affinität gegen das tumorassoziierte Antigen NY-
ESO zu generieren und zu untersuchen, ob solche TZRs aus dem humanen TZR-Repertoire 
generiert werden können. TZRs wurden aus humanen CD4-T-Zellkulturen sowie aus transgenen 
Mäusen isoliert, die ein diverses humanes TZR-Repertoire mit HLA-DRA/DRB1*0401 
Restriktion exprimieren und NY-ESO-negativ sind und somit als Quelle für nicht-tolerante TZRs 
dienen. NY-ESO-reaktive TZRs aus dem Mausmodell zeigten eine bessere Erkennung von 
Tumorzellen und eine höhere Peptidempfindlichkeit als TZRs aus humanen CD4-T-Zellkulturen. 
Wir identifizierten einen TZR-Kandidaten, TZR-3598_2, der, transduziert in CD4-T-Zellen, in 
Kombination mit NY-ESO-spezifischen CD8-T-Zellen in einem Mausmodell der adoptiven T-
Zelltherapie eine Tumorregression verursachte. Eine klinische Version des TZR-3598_2 wurde in 
Vorbereitung einer klinischen Studie auf Funktionalität getestet. Die Daten dieser Arbeit legen 
nahe, dass MHC II-restriktive TZRs gegen NY-ESO von humanisierten nicht-toleranten Mäusen 
eine optimale Affinität im Gegensatz zu humanen TZRs aufweisen und dass der kombinierte 
Einsatz von MHC I- und II-restringierten TZRs gegen NY-ESO die adoptive T-Zelltherapie 








3.1 T cells and the immune system 
The hallmark of the immune system is to distinguish between self and non-self. Through a 
complex interplay of effector cells and molecules, the immune system protects the host from 
external threats like pathogens. The vertebrate immune system can be divided into an innate and 
an adaptive immune system. Effector cells and molecules of the innate immune system rely on 
pattern recognition receptors, that are germ-line encoded and enable a rapid response to invading 
pathogens (Brubaker et al., 2015). In contrast, recognition by the adaptive immune system is 
mediated by antigen-receptors that are highly diverse through somatic recombination and 
recognize almost any antigen in a specific manner. T cells and B cells make up the effector cells 
of the adaptive immune system. Upon recognition of a pathogen, specific T cells and B cells 
expand, and an immune response develops in the course of several days to clear the infection. 
There are different subpopulations of T cells, mainly CD4 and CD8 T cells, which are determined 
by their CD4 or CD8 co-receptor expression. CD8 T cells, also called cytotoxic lymphocytes, kill 
infected host cells and are therefore important for protection against viruses. CD4 T cells are also 
called T helper (Th) cells, because they act primarily on other immune cells. They help CD8 T 
cell and B cell immune responses to develop and are thus important for protection against most 
pathogens. 
 
3.1.1 The T cell receptor 
The antigen receptor of T cells is the T cell receptor (TCR), which was discovered more than 30 
years ago (Hedrick et al., 1984; Yanagi et al., 1984). Each T cell expresses a unique TCR on its 
cell surface, which binds antigenic peptides presented on major histocompatibility (MHC) 
molecules on host cells. The first crystal structures of a TCR in complex with peptide-MHC 
showed a diagonal binding orientation of both molecules (Garboczi et al., 1996; Garcia et al., 
1996). The TCR is composed of a heterodimer of two polypeptides, which in most T cells 
consists of an α and β chain. A minor subset of T cells expresses TCRs composed of γ and δ 
chains (Chien et al., 2014). γδ T cells are rather associated with the innate immune system and 




constant region. The constant regions contain cysteine residues to form an interchain disulphide 
bond and are anchored in the membrane. As the TCR has no intracellular signalling domain, it is 
found in a TCR complex together with CD3 and ζ chain, which recruit signalling proteins upon 
TCR engagement (Call et al., 2002). 
The variable regions of the TCR α and β chains are assembled during T cell development in the 
thymus by TCR gene rearrangement (Samelson et al., 1985). The variable region of the α chain is 
rearranged from many different variable (V) and joining (J) gene segments, the variable region of 
the β chain has a diversity (D) gene segment in addition. V, (D) and J segments are organized in 
the TCRα and β loci on chromosomes 14 and 7 in humans, respectively (Jones et al., 1985; 
Rowen et al., 1996). In addition to the combinatorial diversity by assembly of V, (D) and J genes, 
junctional diversity is created by addition or deletion of nucleotides at the junction when the gene 
segments are joined (Komori et al., 1993). This highly diverse region at the junction of V-J or V-
D-J gene segments is called the complementarity determining region 3 (CDR3) and forms the 
centre of the antigen-binding site of the TCR (Davis and Bjorkman, 1988). Recombination-
activating genes 1 and 2 (RAG-1 and RAG-2) are essential components for V(D)J recombination 
to take place. If one of them is not functional, T cells as well as B cells cannot develop due to the 
inability to properly rearrange antigen receptors and the host is devoid of lymphocytes 
(Mombaerts et al., 1992; Shinkai et al., 1992). 
 
3.1.2 MHC molecules 
MHC I and II genes are organized in the MHC locus together with many other genes important 
for antigen processing and presentation (Beck et al., 1999). There are three MHC I and three 
MHC II molecules encoded, HLA-A, B and C, and HLA-DR, DP and DQ, respectively. MHC I 
and II genes are highly polymorphic (Robinson et al., 2015). Each MHC molecule can bind a 
certain set of peptides that have a similar binding pattern by sharing similar anchor residues (Falk 
et al., 1991). In addition to the polymorphic nature of the MHC molecules, they are co-
dominantly expressed. Therefore, each individual can present a large but different set of peptides 
(Apanius et al., 1997).  
MHC I molecules consist of one α chain with three domains, α1, α2, and α3, and a smaller non-
polymorphic chain, the β2-microglobulin (β2m) (Bjorkman et al., 1987). MHC II molecules 
consist of one α chain and one β chain, each forming two domains, α1 and α2 and β1 and β2, 




allows binding of peptides in the range of 8-11 amino acids. In contrast, the peptide-binding cleft 
in MHC II molecules is open and therefore peptide length is not constrained. Nested sets of 
peptides sharing a core region with different peptide lengths to the sides are found when eluted 
from MHC II (Rammensee, 1995). Although one TCR can recognize peptides on MHC II of 
different lengths, changes in the peptide flanking residues can alter TCR affinity (Cole et al., 
2012). 
MHC I molecules are loaded with peptides from mostly cytosolic and nuclear proteins that are 
degraded by the proteasome and transported into the endoplasmic reticulum by the transporter 
associated with antigen processing (TAP) (Neefjes et al., 2011). Newly synthesized MHC II 
molecules are bound to the invariant chain, which occupies the peptide-binding site of the MHC 
II molecule and targets the complex to late endosomal-lysosomal antigen-processing 
compartments. The invariant chain is cleaved by acidic proteases leaving a short fragment in the 
antigen-binding site, class II-associated invariant chain peptide (CLIP), which is exchanged for 
other peptides catalysed by the molecule HLA-DM (Neefjes et al., 2011). Although most 
peptides loaded on MHC II originate from proteins entering the antigen-binding compartment via 
the endocytic pathway, cytosolic or nuclear proteins can enter the antigen-binding compartment 
via macroautophagy (Schmid et al., 2007). 
 
3.1.3 T cell selection in the thymus 
T cell precursors migrate from the bone marrow to the thymus, where the so called thymocytes 
develop into mature T cells. By passing through a sequence of stages, the thymocytes rearrange 
their T cell receptor genes and undergo positive and negative selection to ensure restriction to the 
individual’s MHC molecules but prevent auto-reactivity. According to the affinity model, the 
strength of the interaction between the TCR and self-peptide-MHC complexes determines the 
fate of the thymocytes (Klein et al., 2014). For positive selection, the TCR must interact weakly 
with self-peptide MHC complexes to be protected from death by neglect. Is the interaction too 
strong, negative selection induces thymocytes to go into apoptosis (Klein et al., 2014). However, 
CD4 T cells with TCRs of too high affinity can differentiate into T regulatory cells (Tregs) 
instead of being negatively selected (Hsieh et al., 2012). Tregs specifically inhibit immune 
responses and thereby play a major role in maintaining self-tolerance. 
To enable effective negative selection of auto-reactive T cells, most proteins of the body are 




The transcription factor autoimmune regulator (Aire) is responsible to turn on peripheral genes in 
epithelial thymic cells and its dysfunction causes autoimmune manifestations in many organs of 
the body (Anderson et al., 2002; Nagamine et al., 1997). More recently, the transcription factor 
Fezf2 was found to turn on tissue-restricted antigens, which are not regulated by Aire (Takaba et 
al., 2015). Deletion of auto-reactive T cells, however, is not always complete (Su et al., 2013; Yu 
et al., 2015). CD8 T cells recognizing the Y chromosome-encoded H-Y antigen were found in 
males, but fewer numbers as compared to females (Yu et al., 2015). In addition to central 
tolerance created in the thymus by deleting auto-reactive thymocytes, peripheral tolerance can be 
induced when auto-reactive T cells have escaped negative selection in the thymus. Clonal anergy 
or deletion occurs when TCR engagement takes place in the absence of inflammatory signals 
(Mueller, 2010). 
 
3.2 Immune responses to cancer 
In a series of tumour transplantation experiments, it was shown that immunization with 
methylcholanthrene (MCA)-induced fibrosarcomas among inbred mice could protect from 
subsequent transplantation challenge using the same tumour (Prehn and Main, 1957). 
Immunization with normal tissues did not confer protection upon tumour challenge and mice 
immunized with tumour transplant did not reject skin-grafts. Therefore, anti-tumour immunity 
was elicited by unique rejection antigens of the tumour (Prehn and Main, 1957). 
 
3.2.1 Immunosurveillance 
While it became clear that T cells can recognize cancer cells, it is an ongoing debate, whether 
immune responses to naturally occurring tumours, as opposed to transplanted tumours, can be 
destructive (Blankenstein, 2007; Vesely and Schreiber, 2013). Immunosurveillance against virus-
induced cancers can be effective as demonstrated by the elevated risk of virus-induced cancers in 
immunocompromised individuals following organ transplantation (Engels et al., 2011). However, 
clear evidence for immunosurveillance of spontaneously occurring tumours is lacking. Although 
immune responses are often detected in cancer patients, by the time a tumour becomes clinically 
evident immune responses have obviously failed to prevent its outgrowth. Whether the immune 
system selects for less immunogenic tumour variants is unclear. Shedding light on this question, 




shown that tumours do not escape under immunological pressure but instead induce a state of 
profound tolerance (Willimsky and Blankenstein, 2005). Although strong immune responses 
were induced during cancer development, they were non-functional. In contrast, immunized mice 
remained tumour-free throughout their life, showing that in principle T cells are capable of 
rejecting the tumours but not when induced in the course of tumour development (Willimsky and 
Blankenstein, 2005). Unresponsive T cells with specificity for tumour antigens were also found 
in patients explaining the lack of benefit of endogenous immune responses (Lee et al., 1999).  
 
3.2.2 Checkpoint blockade 
In the clinical setting, attempts are made to break T cell tolerance induced by the tumour and 
make use of the endogenous anti-tumour immune response. Unresponsive T cells upregulate 
inhibitory receptors like PD-1 and CTLA-4, which can be blocked to unleash tumour-reactive T 
cells (Hirano et al., 2005; Leach et al., 1996). However, only a fraction of patients respond to 
immune checkpoint blockade, and responses are often limited in time (Schachter et al., 2017). T 
cells recognizing self-antigens of the tumour are subject to central tolerance and are therefore of 
low avidity (Aleksic et al., 2012). T cells recognizing mutant neo-antigens of the tumour can be 
of high avidity and are thought to mediate the effect of checkpoint blockade (Gubin et al., 2014; 
McGranahan et al., 2016). However, peripheral tolerance induced by the tumour may be 
irreversible and reduce the number of available tumour-reactive T cells (Philip et al., 2017). 
Thus, one of the reasons for patients not responding to checkpoint blockade may be the lack of 
available tumour-reactive T cells of high avidity. 
 
3.2.3 Tumour antigens 
Tumour antigens are any molecules on cancer cells that can be recognized by T cells (Schreiber, 
2013). Tumour antigens can be divided into two main classes, self-antigens and tumour-specific 
antigens. Self-antigens are non-mutated and encoded in the genomes of all cells but show higher 
or predominant expression in cancer cells (Offringa, 2009). Because self-antigens are not cancer-
specific, they are also referred to as tumour-associated antigens. One subgroup are overexpressed 
proteins such as HER2/neu or Wilms tumour protein 1, which are expressed on normal tissues 
but to a much higher extent in cancer cells (Call et al., 1990; Coussens et al., 1985). Furthermore, 
differentiation antigens are expressed in specific cell lineages and consequently in tumours 




differentiation antigens, such as gp100 and MART-1 (Bakker et al., 1994; Kawakami et al., 
1994). Cancer-testis antigens are self-antigens that are highly expressed in spermatocytes in the 
testis and can be reactivated in cancer cells (Scanlan et al., 2002). Following the identification of 
the first member of this group, MAGE-A1, many more were discovered including BAGE, 
GAGE, NY-ESO and BORIS (Boel et al., 1995; Chen et al., 1997; Loukinov et al., 2002; Van 
den Eynde et al., 1995; van der Bruggen et al., 1991). A great advantage of tumour-associated 
antigens as immunotherapy targets is that they are often shared between tumours. However, 
expression on normal tissues carries the risk of on-target toxicities (Johnson et al., 2009). In 
contrast, tumour-specific antigens are derived from mutations in the tumour and are usually truly 
tumour-specific. Although mutations that give a growth advantage to the tumour (cancer-driver 
mutations) can be recurrently found, they are often individual-specific and thus more difficult to 
target than shared tumour-associated antigens (Vogelstein et al., 2013). Because of the advances 
made in high-throughput sequencing, tumour-specific mutations as immunotherapy targets have 
gained more attention in recent years (Blankenstein et al., 2015). Moreover, proteins from 
oncogenic viruses expressed in cancer cells are tumour-specific antigens and can serve as good 
targets for immunotherapy (Tashiro and Brenner, 2017).  
 
3.3 Adoptive T cell therapy 
3.3.1 Unmodified T cells 
First evidence for the therapeutic effect of adoptive T cell therapy (ATT) came from allogeneic 
stem cell transplantation for the treatment of chronic myeloid leukaemia (Odom et al., 1978). The 
graft-versus-leukaemia effect, the removal of residual leukemic cells, is attributed to T cells 
within the donor graft, as T cell depletion in the transplant caused increased risk of relapse 
(Horowitz et al., 1990). Furthermore, transplants from identical twins increased the risk for 
relapse leading to the assumption that T cells recognize minor histocompatibility antigens 
presented on the leukemic cells (Goulmy, 2004; Horowitz et al., 1990). Unfortunately, the 
clinical benefit of allogeneic stem cell transplantation is limited by graft-versus-host disease, 
which is often associated with the graft-versus-leukaemia effect. 
Furthermore, ATT was applied to treat viral infections, which are common in 
immunocompromised patients following stem cell or organ transplantation. In vitro expanded 




reactivation and the EBV-associated lymphoproliferative disease (Heslop et al., 1996; Riddell et 
al., 1992). Because the generation of virus-specific T cell lines for each individual patient is 
laborious and not possible if the donor lacks viral immunity, banks of multi-virus-specific T cell 
lines have been generated for common HLA antigens that can be given to partially MHC-
matched patients (Leen et al., 2013; Tzannou et al., 2017). 
Efforts have been made to implement ATT for treating non-virus induced cancers. To mobilise 
endogenous tumour-reactive T cells that are muted by tolerance, tumour infiltrating lymphocytes 
(TILs) can be expanded ex vivo and infused back into the patient (Dudley et al., 2005). This 
approach has been widely applied in metastatic melanoma and achieves responses in 
approximately half of the patients with some complete regressions (Dudley et al., 2005). TILs 
from complete responders were shown to contain T cells with specificities against non-mutated 
self-antigens as well as mutated neo-antigens (Lu et al., 2014; Lu et al., 2013; Tran et al., 2014; 
Veatch et al., 2018). As T cells recognizing self-antigens are usually of low avidity and therapy 
responses correlate with predicted neo-antigen load (Lauss et al., 2017), neo-antigen specific T 
cells are thought to mediate the therapeutic effect of TILs. TILs can be expanded non-specifically 
or specifically by stimulation with autologous tumour cells or with cells expressing tumour-
derived epitopes (Dudley et al., 2010; Dudley et al., 2005; Tran et al., 2016). Nevertheless, T cell 
specificities are difficult to control and depend on the presence and functionality of the accessible 
TILs. Therapy success is difficult to predict and cancer entities that have lower mutational burden 
and/or less T cell infiltration may not qualify for TIL therapy. 
 
3.3.2 Engineered T cells 
TCR gene therapy allows the production of high numbers of tumour-reactive T cells by genetic 
engineering of patients’ T cells. Great clinical success has been achieved in treating 
haematological malignancies with T cells engineered with a chimeric antigen receptor (CAR) 
targeting CD19 (Maude et al., 2014). CARs are synthetic receptors that possess the antigen-
binding domain of an antibody and an intracellular signalling domain. Similar to antibodies and 
unlike TCRs, CARs recognize cell surface proteins, which is advantageous regarding no 
requirement for a TCR-matched MHC expression in the patient. However, solid tumours usually 
do not have a unique surface marker and may be better targeted by TCRs that recognize 





3.3.3 CD4 T cells in adoptive T cell therapy 
So far, clinical trials of ATT using TCR-engineered T cells could not achieve comparable success 
to the CAR studies targeting CD19 in haematological malignancies. One underlying reason may 
be that TCR gene therapy trials have mainly focussed on CD8 T cells. However, solid tumours 
may require CD4 T cell help to constitute a full immune response able to achieve major clinical 
effects. 
Experiments with mouse models showed the importance of CD4 T cells for anti-tumour 
immunity already long ago (Greenberg et al., 1981). In an adoptive chemoimmunotherapy study 
CD8-depleted T cells eliminated MHC II-negative leukaemia in mice without the need for 
cytolytic activity (Greenberg et al., 1981; Greenberg et al., 1985). Rejection of MHC II-negative 
tumours by CD4 T cells was also confirmed in other murine tumour models and shown to be 
mediated by interferon (IFN)γ functioning on host cells and not cancer cells (Mumberg et al., 
1999; Perez-Diez et al., 2007; Qin and Blankenstein, 2000). In a mouse model of transplantable 
melanoma, tumour rejection by CD4 T cells was IFNγ-dependent as well, but was mediated by 
direct lysis of MHC II-positive cancer cells (Muranski et al., 2008; Quezada et al., 2010). 
Furthermore, CD4 T cells exert helper function to support CD8 T cells and several cancer models 
require both CD4 and CD8 T cells for improved efficacy of ATT (Arina et al., 2017; Bos and 
Sherman, 2010; Li et al., 2017). T cell help was shown in a mouse model of insulinoma, in which 
CD4 T cells were necessary to recruit CD8 T cells to the tumour site and enhance their cytolytic 
function (Bos and Sherman, 2010). In a mouse model of ATT of established large tumours, CD4 
T cells could prevent or reverse antigen-positive tumour relapse that could not be controlled by 
CD8 T cells alone (Arina et al., 2017). Furthermore, the cooperation of CD4 and CD8 T cells can 
achieve bystander elimination of antigen-loss variants, which are a common problem in the clinic 
(Rapoport et al., 2015; Schietinger et al., 2010). The different mechanisms by which CD4 T cells 
exert tumoricidal effects may reflect the versatility of CD4 T cells, which can differentiate into 
different subpopulations to integrate different types of immune responses (Geginat et al., 2014). 
Interestingly, intratumoural CD4 T cells recognizing neo-antigens were found in several patients 
(Linnemann et al., 2015). Concordantly, two cases of successful TIL therapy were attributed to 
neo-antigen-specific CD4 T cells within the TIL product (Tran et al., 2014; Veatch et al., 2018). 
In another case study, a patient with metastatic melanoma experienced a durable clinical response 
following treatment with expanded NY-ESO-specific CD4 T cell clones, which could however 




these clinical data, as well as the referenced mouse models encourage further application of CD4 
T cells in treatment of cancer. 
However, it has to be noted that CD4 T cells can also negatively influence immune responses. 
CD4 T cells differentiated into Tregs are important to control exaggerated immune responses and 
prevent autoimmunity (Suri-Payer et al., 1998). Because of this immune regulatory property, 
Tregs can hinder anti-tumour immunity. This was shown in a mouse model of transplantable 
melanoma, in which only adoptive transfer of tumour-reactive CD8 T cells in conjunction with 
Treg-depleted CD4 T cells but not undepleted CD4 T cells resulted in cancer regression (Antony 
et al., 2005). Infiltration of Tregs are frequently found in tumour tissue and are implicated in 
suppression of T cell activation (Curiel et al., 2004; Woo et al., 2002). 
 
3.3.4 Clinical studies using engineered T cells 
First TCR gene therapy trials have targeted the melanocyte differentiation antigen MART-1 
(Johnson et al., 2009; Morgan et al., 2006). In the first trial, a low-affinity TCR DMF4 was used 
to treat metastatic melanoma, but only marginal responses were seen in two of 17 patients 
(Morgan et al., 2006). In a next clinical trial, TCRs recognizing MART-1 (DMF5) or gp100 with 
higher affinity were used. Although objective responses of 19% and 30%, respectively, were 
seen, both TCRs recognized normal melanocytic cells resulting in toxicities in the skin, eye and 
ear (Johnson et al., 2009). On-target off-tumour toxicity was also seen when three patients were 
treated with a high-affinity TCR targeting carcinoembryonic antigen (Parkhurst et al., 2011). This 
shows that appropriate TCR affinity is crucial to achieve anti-tumour effects but at the same time 
results in on-target off-tumour toxicity, if the target antigen is not exclusively expressed by the 
tumour. In two clinical trials targeting the cancer-testis antigen MAGE-A3, off-target toxicities to 
cardiac and brain tissue, respectively, caused fatal toxicities (Linette et al., 2013; Morgan et al., 
2013). Both TCRs were affinity-matured to increase their potency, suggesting that in vitro 
maturation increases the risk for off-target toxicity by circumventing negative selection in the 
thymus. In two clinical trials, the cancer-testis antigen NY-ESO was targeted in melanoma or 
synovial sarcoma and multiple myeloma (Rapoport et al., 2015; Robbins et al., 2015). Although 
an affinity-matured TCR was used, no toxicities were observed but objective responses were seen 
in 61%, 55% and 80% in sarcoma, melanoma and myeloma patients, respectively (Rapoport et 
al., 2015; Robbins et al., 2015; Robbins et al., 2008). Lack of toxicity is in line with the absence 




Gotter et al., 2004). However, one fatal severe adverse event caused by bone marrow failure was 
reported following TCR gene therapy using the same affinity-matured TCR against NY-ESO 
(Mackall et al., 2017). Moreover, it has to be noted that in the myeloma study, patients received 
high-dose chemotherapy and autologous stem cell therapy prior to the engineered T cells, making 
interpretation on efficacy of the engineered T cells difficult. However, an inverse correlation of 
NY-ESO expression (or LAGE-1, containing the targeted epitope) and engineered T cell 
persistence suggests efficacy of the T cell therapy (Rapoport et al., 2015). 
 
3.3.5 Critical factors for T cell gene therapy 
Several studies have shown that anti-tumour efficacy and on-target off-tumour toxicity cannot be 
separated if the antigen is expressed in normal tissues (Johnson et al., 2009; Morgan et al., 2006; 
Parkhurst et al., 2011). This was confirmed in a mouse model of ATT, in which TCR affinities 
against gp100209-217 correlated equally with anti-tumour and autoimmune activity (Zhong et al., 
2013). Therefore, selection of a target antigen whose expression is restricted to cancer cells is of 
utmost importance to prevent toxicity. 
Furthermore, human and mouse studies have shown that only TCRs of higher affinity can reach 
anti-tumour efficacy (Johnson et al., 2009; Morgan et al., 2006; Obenaus et al., 2015; Zhong et 
al., 2013). It was suggested that TCR affinity should be at least Kd=10 µM (Zhong et al., 2013). 
We defined optimal-affinity TCRs as TCRs that can be found in immune responses to foreign 
antigens, such as viral antigens (Obenaus et al., 2015). Virus-specific TCRs have an affinity 
around 10 µM (Aleksic et al., 2012). However, T cell avidity does not only depend on TCR 
affinity but also on TCR density on the T cell surface, why it is difficult to draw a strict line of 
required TCR affinity. Moreover, the interaction of the TCR and the peptide-MHC complex is 
not only dependent on TCR affinity but also on the affinity of the peptide to MHC. It was shown 
that only high-affinity peptides serve as rejection epitopes leading to relapse-free tumour 
regression (Engels et al., 2013). Further, mouse studies showed that tumour rejection or relapse 
following ATT can be dependent on the strength of antigen expression (Leisegang et al., 2016a; 
Spiotto et al., 2004). Only high antigen expression caused tumour rejection, which in one mouse 
model correlated with antigen cross-presentation by tumour stroma (Spiotto et al., 2004).  
Together, TCR affinity to peptide-MHC complex, peptide affinity to MHC and abundance of the 
target antigen are important factors for success of ATT. As the ideal situation, high TCR and 




combination therapies such as targeting more than one antigen and/or combined use of CD4 and 
CD8 T cells may be required for tumour rejection. 
 
3.4 Aims of this doctoral thesis 
Based on the importance of CD4 T cells in anti-tumour immune responses, the aim of the present 
project was to generate MHC II-restricted TCRs for the use in ATT. As target antigen we 
employed the shared tumour antigen NY-ESO to allow for broad application of potential 
therapeutic TCRs (Chen et al., 1997). To raise optimal-affinity TCRs against NY-ESO, human 
TCR gene loci/chimeric MHC II transgenic (ABabDR4) mice were employed (Ito et al., 1996; Li 
et al., 2010). Moreover, we asked, whether the human repertoire can be used as a source for 
MHC II-restricted TCRs against NY-ESO. 
 
3.4.1 NY-ESO as target for ATT 
NY-ESO is a tumour-associated antigen that was found by serological expression cloning 
(SEREX) from an oesophageal cancer (Chen et al., 1997). In addition to oesophageal cancer, 
NY-ESO expression was found in a variety of cancers including melanoma, breast cancer and 
prostate cancer. Moreover, NY-ESO is expressed highly in male germ cells and to some extent in 
ovary and/or placenta (Chen et al., 1997). Besides expression in the thymus, trace amounts of 
NY-ESO mRNA have been found in somatic tissues including liver and pancreas, but the 
relevance of this finding is unclear (Gotter et al., 2004; Sato et al., 2005). Absence of NY-ESO 
expression in normal tissues is suggested by lack of toxicity in two clinical studies in which NY-
ESO was targeted by ATT (Rapoport et al., 2015; Robbins et al., 2015). 
The expression of NY-ESO in medullary thymic epithelial cells may lead to deletional tolerance 
of high-avidity T cells against NY-ESO (Gotter et al., 2004). This could be one of the reasons 
why spontaneous anti-NY-ESO immunoglobulin (Ig)G antibody and CD4 responses in cancer 
patients do not lead to a clinical benefit and why NY-ESO immunization strategies as cancer 
treatment failed (Fourcade et al., 2014; Gnjatic et al., 2003; Takeoka et al., 2017; Zeng et al., 
2000). Furthermore, the treatment success achieved in one patient with expanded NY-ESO-
specific CD4 T cell clones could not be reproduced in eight other patients (Hunder et al., 2008; 




ESO cannot be harnessed for cancer therapy. However, due to its restricted expression pattern, 
NY-ESO may be a good target for adoptive therapy using high-avidity T cells. 
 
3.4.2 ABabDR4 mouse model 
As highly functional TCRs may not be found in the human repertoire due to NY-ESO expression 
in the thymus and concomitant tolerance induction (Gotter et al., 2004), ABabDR4 mice were 
used for TCR generation (Chen et al., 2017; Ito et al., 1996; Li and Blankenstein, 2013; Li et al., 
2010). ABabDR4 mice were generated by crossing HLA-DRA-IE/HLA-DRB1*0401-IE (HLA-
DR4-IE)-chimeric MHC II-transgenic mice (DR4 mice) with human TCR gene loci-transgenic 
mice (ABab mice) (Ito et al., 1996; Li et al., 2010). DR4 mice were engineered to express a 
chimeric MHC II molecule which consists of the antigen-binding domains from the human HLA-
DR4 and the membrane-proximal domains from the murine I-Ed to enable murine CD4-binding 
(Ito et al., 1996). DR4 mice mounted a specific CD4 T cell response to heamagglutinin307-319 
upon immunization and develop experimental allergic encephalomyelitis symptoms when 
immunized with HLA-DR4 epitopes from myelin basic protein or proteolipid protein (Ito et al., 
1996). ABabDR4 mice were shown by deep sequencing to rearrange a diverse repertoire of 
human TCRs (Chen et al., 2017). Interestingly, TCR diversity of CD4 T cells from ABabDR4 
mice, in which both TCRs and MHC II are human, was higher than from ABabHHD mice, in 
which TCRs are human but MHC II from mouse. This suggests that human TCR genes and 
human MHC co-evolved (Chen et al., 2017). Importantly, ABabDR4 mice express a TCR 
repertoire which was not influenced by NY-ESO-specific tolerance, as mice do not express 
homologous sequences to the HLA-DR4-restricted NY-ESO epitope used in this project. In 
ABabDR4 mice, NY-ESO is a foreign antigen. 
 
3.4.3 Steps to be taken 
First, the ABabDR4 mouse model was characterized in terms of MHC II expression and the 
ability to mount CD4 T cell responses. Next, immunogenicity of the chosen HLA-DR4-restricted 
NY-ESO epitope in the ABabDR4 mice was shown. TCRs isolated from immunized ABabDR4 
mice were compared in functional assays to TCRs isolated from in vitro primings of human CD4 
T cells to investigate which source is appropriate to derive optimal-affinity TCRs against NY-
ESO. To analyse whether clinical application of the chosen TCR candidate can be safe, it was 




and a clinical version of the chosen TCR candidate was analysed for comparability to the 
preclinical version used in the development phase. 
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4 Materials & Methods 
 
4.1 Cell lines 
The human melanoma cell lines FM-82, FM-56 (both NY-ESO+, HLA-DR4+), FM-3 (NY-ESO-, 
HLA-DR4+) and FM-6 (NY-ESO+, HLA-DR4-) were provided by the European Searchable 
Tumour Cell Bank and Database (ESTDAB). Jurkat 76/CD4 cells are TCR-deficient and were 
generated by introducing human CD4 into the Jurkat 76 clone (Heemskerk et al., 2003). The 
murine cell line T.54ζ17 is TCR-deficient and expresses human CD4 and murine ζ chain 
(58/CD4 cells) (Kieback et al., 2016). The cell line K562/DR4 was generated by transducing 
K562 cells with HLA-DRA and HLA-DRB1*0401. All cell lines were cultured in RPMI 
supplemented with 10% fetal calf serum (FCS; PAN Biotech) and 1x antibiotic-antimycotic. The 
retroviral packaging cell lines 293GP-GLV (GALV cells) and Plat-E (producing amphotropic and 
ecotropic retroviral vectors, respectively) were cultured in DMEM supplemented with 10% FCS 
(Ghani et al., 2009; Morita et al., 2000). The panel of EBV–transformed lymphoblastoid B cell 
lines (LCLs) were cultured in RPMI supplemented with 10% FCS, 1x antibiotic-antimycotic, 1 
mM sodium pyruvate and 1x non-essential amino acids. All cell culture reagents were purchased 
from Life Technologies unless otherwise indicated. 
 
4.2 Mouse strains 
All animal experiments were performed according to national guidelines and were approved by 
the responsible national institute (Landesamt für Gesundheit und Soziales, Berlin, Germany). All 
mouse strains were housed at the animal facility of the Max Delbrück Centrum for Molecular 
Medicine under specific-pathogen-free conditions. DR4 mice express a mouse/human chimeric 
MHC II molecule, HLA-DR4-IE, and are deficient for mouse MHC II molecules (Ito et al., 
1996). They were purchased from Taconic. ABabDR4 mice are transgenic for the entire human 
TCRα and β loci and a mouse/human chimeric MHC II molecule, HLA-DR4-IE, while neither  
mouse TCRs nor mouse MHC II molecules are expressed (Chen et al., 2017). They were 
generated by crossing human TCR loci-transgenic mice (ABab) and DR4 mice (Ito et al., 1996; 
Li et al., 2010).   DR4xRag-/-   mice were  generated  by  crossing  DR4  mice  with  Rag-/-  mice. 




Table 1. Genotyping of ABabDR4 mice. Displayed are PCR primers used to detect the transgenes 
human TCRα and TCRβ loci (hTCRa, hTCRb), HLA-DRA-IE (DR4A), HLA-DRB1*0401-IE (DR4B), as 
well as knockouts of mouse TCRα and TCRβ constant regions (mTCRa, mTCRb) and I-A β-chain (I-Ab). 
 
 
Primers Gene/product Product size PCR 
program 
Forward/reverse 








691 bp standard cacattaggccaggagaagc/ 
cctgcttagtggctgagtgg 
mTCRa WT Mouse TCRα 
constant region 
164 bp standard actgtgctggacatgaaagc/ 
ccatagatttgagccaggagg 
mTCRb WT Mouse TCRβ 
constant region 
229 bp standard tgagccatcaaaagcagaga/ 
gaagtggttgcaaggattgt 
mTCRa KO Knockout in 
mouse TCRα 
constant region 
180 bp standard taccggtggatgtggaatgt/ 
actgtgctggacatgaaagc 
mTCRb KO Knockout in 
mouse TCRβ 
constant region 




1276 bp elongation 1 











~ 940 bp standard gatggattgcacgcaggttct/ 
tctgcacaccgtgtccagct 






226 bp in WT 
(haplotype b) 
1376 bp in I-
Abneo 
elongation 1 
min 30 sec 
tttcgtgtaccagttcatgg/ 
gtagttgtgtctgcacaccg 




1035 bp in 
B6 
~ 1720 in 
Balb/c 
elongation 1 
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OTIIxRag+/- and P14xRag-/- mice express transgenic TCRs with specificity for ovalbumin323-339 
presented on I-Ab and lymphocytic choriomeningitis virus glycoprotein33-41 presented on H2-Db, 
respectively (Barnden et al., 1998; Pircher et al., 1989). Mice were genotyped by polymerase 
chain reaction (PCR) using DNA isolated from ear biopsies by alkaline lysis. 300 µl 0.05 M 
NaOH were added to the ear biopsy and incubated at 95°C for one hour. For neutralization, 30 µl 
of stopping solution were added containing 1 M Tris-Cl and 10 mM EDTA at pH 8.0. PCR 
reactions were performed in a total volume of 10 µl, using 1 µl lysed DNA, 0.1 µl Taq DNA 
polymerase (FastStart, Roche), 0.2 mM dNTPs and 0.5 µM primers. Thermocycling conditions 
for standard PCR were as follows: 1) Initial denaturation step at 95°C for 5 min, 2) denaturation 
at 95°C for 30 sec, 3) annealing at 63°C for 40 sec, 4) elongation at 72°C for 1 min 10 sec, 5) 35 
cycles steps 2)-4), 6) final elongation at 72°C for 10 min. Table 1 lists PCR primers used for 
genotyping of ABabDR4 mice. 
 
4.3 Immunization of mice 
ABaBDR4, DR4 and C57BL/6 mice were taken for immunization at 6-16 weeks of age. For 
peptide immunization, 100 µg of the NY-ESO peptide 116-135 (LPVPGVLLKEFTVSGNILTI, 
NY-ESO116, GenScript) or Pan-DR binding peptide (AK(X)VAAWTLKAA, (X) = 
cyclohexylalanine; Padre, Biomatik; Alexander et al., 1994) and 50 µg CpG (CpG 1826, 
MOLBIOL) were prepared in 200 µl 1:1 emulsion of incomplete Freund’s adjuvant and 
phosphate-buffered saline (PBS) and injected s.c. into the flank of the mouse. Immunizations 
were repeated with at least 4-week intervals. For DNA immunizations, the Helium Gene Gun 
system from Biorad was used. A mixture of pcDNA3.1 vectors containing NY-ESO cDNA or 
granulocyte macrophage colony-stimulating factor cDNA were precipitated on gold microcarriers 
of 1 µm diameter at a DNA loading rate of 2 µg/mg gold. For cartridge preparation, the 
DNA/microcarrier suspension in 0.05 mg/ml polyvinylpyrrolidone in Ethanol (both Sigma) was 
loaded into Gold-Coat tubing using a Tubing Prep Station (Biorad). Using Helium pressure, 
DNA from two cartridges was delivered into the shaved skin at the abdomen of the mouse. 
 
4.4 Evaluation of immune response 
CD4 T cell responses were analysed in peripheral blood or cells from spleen and draining lymph 
nodes one week after immunizations. 200 µl blood or cells from spleen and draining lymph nodes 
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were lysed by 1 ml or 3 ml ammonium-chloride-potassium lysing buffer (ACK buffer; 155 mM 
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 2 min followed by two washes with PBS containing 
2% FCS. Cells were resuspended with mouse T cell medium (mTCM; RPMI supplemented with 
10% FCS, 1x antibiotic-antimycotic, 1 mM sodium pyruvate, 1x non-essential amino acids, 1 
mM HEPES, 50 µM β-mercaptoethanol) and cultured with 1 g/ml NY-ESO116 peptide, Padre or 
a peptide from nonstructural protein 3 (NS3) from hepatitis C virus 
(YAAQGYKVLVLNPSVAAT) as negative control or 4x105 dynabeads T activator CD3/28 
(Invitrogen) as positive control overnight. One third of the blood sample or 1x106 splenocytes 
were applied per well of a 96-well plate. After 2 hrs of incubation, Brefeldin A (Becton 
Dickinson (BD) GolgiPlug) was added to the cultures and intracellular IFNγ staining was carried 
out for analysis (see flow cytometry). 
 
4.5 In vitro expansion of NY-ESO-reactive CD4 T cells from ABabDR4 mice 
For in vitro expansion of NY-ESO-reactive CD4 T cells, cells from spleen and draining lymph 
nodes from mice 10-14 days after the last immunization were prepared and meshed through a 
sieve to yield a single cell suspension. Without prior lysis of erythrocytes, but counting only 
peripheral blood mononuclear cells (PBMC), 1,5x107 cells per well were cultured in a 24-well 
plate in mTCM (supplemented with 20 U/ml IL-2) and in presence of 10-8 M or indicated 
concentration of NY-ESO116 or dynabeads T activator CD3/CD28 at a ratio of 1:1. After one 
week, expansion of NY-ESO-reactive CD4 T cells was analysed by peptide restimulation and 
intracellular IFNγ staining as described. The next day, cells were stained by tetramer and sorted 
by flow cytometry.  
 
4.6 Mouse IFNγ secretion assay 
For T cell isolation, spleen and draining lymph nodes were prepared from mice 10-14 days after 
the last immunization as single cell suspension. Following lysis of erythrocytes by ACK buffer, 
1x106 cells per well were cultured 8 hrs in a 96-well plate in mTCM in presence of 0.5 µM NY-
ESO116 or Padre or 1x106 dynabeads T activator CD3/28 (Invitrogen) as negative and positive 
control, respectively. The responding cells were labelled by Mouse IFNγ Secretion Assay 
(Milteny) as follows. Cultured cells were harvested and washed twice with magnetic-activated 
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cell sorting (MACS) buffer (PBS, 0.5%, bovine serum albumin, 2 mM EDTA). Cells were 
stained by IFNγ Catch Reagent for 5 min, then diluted with warm mTCM and incubated 45 min 
on a rotator at 37°C. After two washes with MACS buffer, cells were stained by IFNγ Detection 
Antibody and anti-mCD4 and anti-mCD3. Prior to cell sorting by flow cytometry, 7-AAD (BD) 
was added to the sample for exclusion of dead cells. 
 
4.7 In vitro priming of human CD4 T cells 
To expand human NY-ESO-reactive CD4 T cells, peripheral blood leukocytes (PBLs) from a 
HLA-DR4+ donor were enriched for CD4 by magnetic separation using a negative selection kit 
(Milteny). Subsequently, the enriched CD4 T cells were stained with TRBV2-PE antibody 
(Beckman Coulter, clone IMMU 546) and enriched by anti-PE microbeads by magnetic 
separation over a LS column yielding 68% TRBV2+ CD4 T cells. 1,9x106 TRBV2-enriched CD4 
T cells were cultured with 2,5x106 irradiated (30 Gy) autologous CD4- cells as feeder cells and in 
presence of 2 M NY-ESO116 in human T cell medium (hTCM; RPMI supplemented with 10% 
FCS, 1x antibiotic-antimycotic, HEPES 1 mM, 10 U/ml IL-2). After 14 days, NY-ESO-reactive 
CD4 T cells were stained by tetramer and sorted by flow cytometry. 
 
4.8 TCR isolation 
From all T cell sorts (yielding between 500-10,000 cells), total RNA was extracted (RNeasy 
Micro Kit, Qiagen) and 5’rapid amplification of cDNA ends (RACE) PCR was performed using 
the SMARTer RACE cDNA Amplification Kit (Clontech). Following cDNA synthesis 
performed according to the Clontech user manual, 5’RACE PCR was performed in a 50 µl 
volume, with 0.5 µl Phusion High-Fidelity DNA polymerase (New England Biolabs), 10 mM 
dNTPs, 1x universal primer mix (Clontech) and 0.5 µM reverse primer. As reverse primers, 
5’cggccactttcaggaggaggattcggaac3’ (for TCRα chain) and 5’ccgtagaactggacttgacagcggaagtgg3’ 
(for TCRβ chain) were used. Thermocycling conditions applied were as follows: 1) initial 
denaturation step at 98°C 2 min, 2) 5 cycles containing a denaturation step at 98°C 30 sec and an 
annealing/elongation step at 72°C for 45 sec, 3) 5 cycles containing denaturation at 98°C 30 sec, 
annealing at 70°C 20 sec, elongation at 72°C 45 sec, 4) 25 cycles containing denaturation at 98°C 
20 sec, annealing at 68°C 20 sec, elongation at 72°C 45 sec, 5) final elongation at 72°C 5 min. 
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The RACE PCR products were purified from an electrophoresis gel and cloned into TOPO 
vectors (Zero Blunt TOPO PCR cloning Kit) to transform competent E. coli. Depending on 
clonality, 6-32 clones per TCR chain were analysed and the most frequent TCRαβ chain pairs 
were tested for function. 
 
4.9 Generation of pMP71 vectors for TCR expression 
If the isolated TCR chains were not clonal, they were cloned as single TCR chains into the 
retroviral vector pMP71-PRE (pMP71) for combinatorial expression to identify functional 
TCRαβ pairs (Engels et al., 2003). For this, the variable TCR region was amplified from a TOPO 
vector and equipped by overlapping extension PCR with the murine constant region amplified 
from the codon-optimized TCR-3600. The generated product was purified, digested and ligated 
into the pMP71 vector. Table 2 lists the primers used for cloning of single TCR chains. 
Functional TCRαβ pairs were synthesized as expression cassettes containing codon-optimized 
TCRβ and TCRα chains linked by the porcine teschovirus-1-derived self-cleaving peptide P2A 
(Leisegang et al., 2008). Constant regions were murinized (Cohen et al., 2006). The synthesized 
expression cassette (GeneArt) was cloned into pMP71. TCR-5712 differs from TCR-3600 only in 
one amino acid and was generated from TCR-3600 by PCR-induced mutagenesis. A clinical 
version of TCR-3598_2 was synthesized containing human constant regions with amino acid 
exchanges at 9 positions corresponding to the murine constant regions and an additional 
disulphide bond (Cohen et al., 2007; Sommermeyer and Uckert, 2010). 
 
4.10 Retroviral transduction 
4.10.1 Human T cells 
Virus supernatant for retroviral transduction of human cells was produced by transfecting GALV 
cells (Ghani et al., 2009) with the retroviral vector pMP71 (Engels et al., 2003) containing a TCR 
expression cassette or a single TCR chain using Lipofectamine2000 transfection reagent (Thermo 
Fisher Scientific). Viral supernatant was harvested after 48 and 72 hrs following transfection and 
used directly for transducing target cells or were stored at -80°C for later use. PBMCs were 
isolated from blood using Pancoll Separating Medium (PAN Biotech) and were depleted of CD8 
T cells  by magnetic separation over a LS column using  CD8 microbeads (Milteny).  1x106 CD8- 




Primers for amplification of variable regions 
Name Sequence 5’→ 3’ 
TRAV9-2_Not1 (fwd) gcattgcggccgccatgaactattctccaggcttagtatc 
TRAV12-3_Not1 (fwd) gcattgcggccgccatgatgaaatccttgagagttttac 
TRAV13-1_Not1 (fwd) attgcggccgccatgacatccattcgagctg   
TRAV20_Not1 (fwd) attgcggccgccatggagaaaatgttggagtgtgc 
TRAV21_Not1 (fwd) attgcggccgccatggagaccctcttgggcc     
TRAV36_Not1 (fwd) attgcggccgccatgatgaagtgtccacaggc           
TRAV38_Not1 (fwd) attgcggccgccatgacacgagttagcttgctg          
TRBV2_Not1 (fwd) gcattgcggccgccatggatacctggctcgtatgc 
TRBV_15_Not1 (fwd) gcattgcggccgccatgggtcctgggcttctc 
V(D)J_alpha_rvs agctggtacacggcaggctcggggttctg      
V(D)J_beta_rvs (if TRAC2) accttggggggggtcacgtttctcagatcc  
J1-1_ms_beta_rvs (if TRAC1) ggtcacgtttctcagatcctctacaactgtgagtctggtgcc 
J1-2_ms_beta_rvs (if TRAC1) ggtcacgtttctcagatcctctacaacggttaacctggtcc  
J1-3_ms_beta_rvs (if TRAC1) ggtcacgtttctcagatcctctacaacagtgagccaacttccc 
J1-5_ms_beta_rvs (if TRAC1) ggtcacgtttctcagatcctctaggatggagagtcgagtcc  
J1-6_ms_beta_rvs (if TRAC1) ggtcacgtttctcagatcctctgtcacagtgagcctggtcc  
Primers for amplification of mouse constant regions 
Name Sequence 5’→ 3’ 
alpha_ms_fwd      atatccagaaccccgagcctgccgtgtacc     
beta_ms_fwd      ggatctgagaaacgtgaccccccccaaggt  
TCR3600_beta_EcoR1_rvs actgaattctcagctgttcttcttcttgaccatgg 
huTCR3600_rvs     caggaattctcatcagctggaccac 
huTCR3600_Mfe1_rvs     agtgcaattgtcagctggaccacagc          
Table 2. Primers used for cloning of single TCR chains. Displayed are PCR primers used to generate 
single TCR chains equipped with murine constant regions by overlap extension PCR. 
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depleted PBMCs per well were activated on anti-CD3 (OKT3)/anti-CD28 (CD28.2; both BD 
Pharmingen)-coated 24-well plates in 1 ml hTCM (supplemented with 300 U/ml IL-2). The first 
transduction was performed 2 days after T cell activation by spinoculating the T cells with 1 ml 
virus supernatant for 90 min at 32°C and 800 g. The second transduction was performed the 
following day on virus-pre-loaded retronectin (Takara)-coated plates. Non-tissue-treated 6-well 
plates were coated with 1 ml retronectin (25 µg/ml in PBS) per well at 4°C overnight, blocked 30 
min with 2% bovine serum albumin (Sigma-Aldrich) in PBS at 37°C and spinoculated with 3 ml 
virus supernatant per well for 2 hrs at 32°C and 2000g. Following removal of the virus 
supernatant, T cells were transferred and spinoculated for 30 min at 800g. After expanding the T 
cells for one week, they were cultured in hTCM (supplemented with 30 U/ml IL-2) for 3 days 
before using them in in vitro experiments or freezing them for later use. Jurkat 76/CD4 cells were 
transduced twice on two subsequent days by spinoculating 5x105 cells with 1 ml virus 
supernatant per well in a 24-well plate for 90 min. For transduction of combinations of single 
TCR chains, virus supernatants were mixed. 
 
4.10.2 Mouse T cells 
Virus supernatant for retroviral transduction of mouse cells was produced by transfecting Plat-E 
cells as described for the GALV cells. TCR-transgenic mice were used as T cell donors. For CD4 
T cells, spleen and lymph nodes from OTIIxRag+/- mice were prepared and subjected to magnetic 
separation of CD4 T cells by negative selection (Milteny). 1x106 isolated CD4 T cells per well 
were activated on an anti-CD3/anti-CD28-coated 24-well plate in 1 ml mTCM (supplemented 
with 30 U/ml IL-2). The first transduction was performed 48 hrs after T cell activation by 
spinoculating the T cells with 1 ml virus supernatant for 90 min at 32°C and 800g. The following 
day the transduction was repeated. After the second transduction CD4 T cells were cultured in 
mTCM supplemented with IL-15 and IL-27 (each 50 ng/ml). For CD8 T cells, spleens from 
P14xRag-/- were prepared and activated by soluble anti-CD3/anti-CD28 (1 µg/ml/0.1 µg/ml) in 
mTCM. One day after T cell activation, the first transduction was performed on virus-pre-loaded 
retronectin-coated 24-well plates. The coating procedure was as described for transduction of 
human T cells but using 1 ml virus supernatant per well. 1x106 activated T cells with 4x105 
dynabeads T activator CD3/CD28 per well were spinoculated for 30 min at 32°C and 800g. A 
second transduction was performed by adding 1 ml virus supernatant and spinoculating the cells 
under the same conditions but 90 min. Afterwards, CD8 T cells were cultured in mTCM 
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supplemented with IL-15 (50 ng/ml). One day (CD4 T cells) or 2 days (CD8 T cells) following 
the second transduction, surface staining was carried out to determine transduction efficiency and 
the T cells were used for ATT or frozen for later use in in vitro assays. 58/CD4 cells were 
transduced twice on two subsequent days by spinoculating 5x104 cells with 100 µl virus 
supernatant per well in a 96-well plate for 90 min. 
 
4.11 Co-culture experiments 
All co-culture experiments with human cells were performed by incubating 1x104 transduced 
CD4 T cells with 5x104 target cells in round bottom 96-well plates for 16-18 hrs. Transduction 
efficiencies were in the range of 30-70% and T cells were calculated accordingly. IFN or IL-2 
was measured in the supernatant by enzyme-linked immunosorbent assay (ELISA; BD OptEIA) 
according to the user manual but applying half volumes throughout the protocol. 50 ng/ml 
Phorbol 12-myristate 13-acetate (PMA) and 5 µg/ml Ionomycin were added to T cells alone as 
positive control. NY-ESO peptides (LPVPGVLLKEFTVSGNILTI, NY-ESO116-135 or 
PGVLLKEFTVSGNIL, NY-ESO119-133) were added at 10-6 M or at indicated concentrations. 
Alanine-exchanged NY-ESO119 peptides (all Genscript, >95% purity) were added at 10-7 M. 
Peptides containing the TCR 3598_2 recognition motif -L-K-E-F- (JPT Peptide Technologies, 
unpurified) were added to the co-culture at 10-6 or 10-7 M as indicated. HLA-DR and HLA-ABC 
blocking antibodies (L243, W6/32; Biolegend) were added to the target cells at 20 g/ml and 
incubated at least 1 hr prior to adding the T cells. Statistic tests and bar charts were made with 
GraphPad Prism (version 7). 
 
4.12 Flow cytometry 
The following antibodies were used for staining at 1:100 ratio and purchased from BioLegend 
unless otherwise indicated: anti-I-Ek-FITC (17-3-3), anti-I-Ad-PE (AMS-32.1), anti-I-Ab-FITC 
(AF6-120.1), anti-mCD4-FITC (RM4-5), anti-mCD4-BV421 (RM4-5), anti-mCD8-PECy7 (53-
6.7, Beckton Dickinson (BD)), anti-mCD3-PE (145-2C11; 1:200), anti-mIL-2-APC (JES6-5H4), 
anti-mIFN-BV421 (XMG1.2), anti-mTCRβ chain-APC (H57-597), anti-hCD4-PE/Cy7 (OKT4), 
anti-hCD3-APC (SK7), anti-hTRBV2-FITC (IMMU 546, 1:20, Beckman Coulter), anti-HLA-
DR-APC (L243). 
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Immune responses of immunized ABabDR4 mice were analyzed by intracellular IFN staining of 
peptide-restimulated blood samples in a 50 µl volume. After Fc blocking for 15 min at 4°C (anti-
mCD16/32, clone 93, Biolegend), cells were washed with PBS and stained with LIVE/DEAD™ 
Fixable Aqua Dead Cell Stain Kit (1:1000 in PBS, Life technologies) for 30 min at 4°C. After 
two washes cells were fixed (BD Cytofix/Cytoperm), washed twice (BD Perm/Wash buffer) and 
stained with antibodies for 30 min at 4°C. Before measuring, cells were washed with BD 
Perm/Wash buffer and resuspended in PBS. 
For tetramer staining, cells were incubated in hTCM containing 10 µg/ml DR4/NY-ESO116 
tetramer or DR4/CLIP87-101 control tetramer for 1 hr at 37°C. Subsequently, antibodies were 
directly added and the cells were incubated 30 min on ice. After two washes with PBS, cells were 
analysed. PE-labelled DR4/NY-ESO116 and DR4/CLIP87-101 tetramers were obtained through the 
NIH Tetramer Facility. 
Adoptively transferred T cells were analysed in 50 or 100 µl peripheral blood. Antibodies were 
added into the blood sample and after 20 min at room temperature, 500 µl of erythrocyte lysing 
solution (BD) was added. After 2 minutes the cells were washed with PBS and the pellet was 
resuspended with 150 µl PBS. The entire sample was analysed by flow cytometry and the number 
of T cells were calculated according to 50 or 100 µl peripheral blood. Significance testing (t test) 
was performed with GraphPad Prism (version 7). 
FACSAriaTM II was used for sorting of cells and FACSCanto II or LSRFortessa were used to 
acquire cells for analysis (all BD). Flow cytometry data were analysed with FloJo version 10.1.  
 
4.13 Western blot 
5x106-1x107 cells were used for protein extraction with cell lysis buffer (Mammalian Cell Lysis 
Kit, Sigma). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed with 50 ug protein per sample, which was heated before at 70°C for 10 min in lithium 
dodecyl sulfate sample buffer and sample reducing agent. Samples were run in a 10% 
polyacrylamide gel (bis-tris) in 2-morpholinoethanesulfonic acid SDS running buffer at 140 V for 
1 hr. Proteins were blotted onto a methanol-activated polyvinylidene difluoride (PVDF) 
membrane in transfer buffer for 45 min at 20 V (all buffer and components from Novex, Life 
Technologies). Subsequently, the membrane was incubated in blocking buffer (PBS, 5% milk 
powder, 0,05% Tween20) for 1 hr at room temperature and then incubated with anti-NY-ESO 
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antibody 1:750 (E978, Sigma) at 4°C overnight. After washing the membrane 3 times in PBST 
(PBS, 0,05% Tween20), it was incubated with goat anti-mouse IgG conjugated to horse radish 
peroxidase (HRP; Santa Cruz Biotechnology) 1:5000 in blocking buffer for 1 hr. Following 3 
washes with PBST, the membrane was analysed by applying Western blotting Luminol Reagent 
(Santa Cruz) and chemiluminescence was detected by Lumi-Imager F1 (Roche). For loading 
control, actin was analysed after incubation of the membrane with anti-actin-HPR (AC-15, 
Sigma) 1:30000 for 1 hr at room temperature and 3 PBST washes. 
 
4.14 Mouse model of adoptive T cell therapy of cancer 
A fibroblast line originating from a TREloxPstoploxPTagLuc transgenic mouse (Tet-TagLuc cells, 
Anders et al., 2011) was retrovirally transduced with HLA-A2 harbouring the murine H-2Db α3 
domain and fused to human β2m (HHD, Pascolo et al., 1997) and full-length NY-ESO with 
mCherry reporter expression from IRES to create Tet-TagLuc-NY-ESO-HHD cells. A cell clone 
(Tet-TagLuc-NY-ESO-HHD clone 1) was used for subcutaneous tumour challenge of 
DR4xRag2-/- recipient mice. After 30 days, tumours were palpable and the mice were treated with 
1x106 CD4 T cells from OTIIxRag+/- mice transduced with TCR-3598_2 and/or 1x106 CD8 T 
cells from P14xRag1-/- mice transduced with TCR-ESO (Obenaus et al., 2015). As controls, CD4 
and CD8 T cells were transduced with TCR-1367 recognizing MAGE-A1 on HLA-A2 (Obenaus 
et al., 2015). Tumour volumes were determined two or three times per week and were calculated 
by multiplying the three dimensions of the tumour divided by two.  
To isolate CD11b+ stromal cells, tumour pieces were incubated on a rotator at 37°C in RPMI 
containing 1 mg/ml collagenase II (Gibco), 1 mg/ml dispase II and 10 µg/ml DNase I (Roche). 
After one hour, 1x trypsin-EDTA (Gibco) was added for further incubation of 30 min. The 
filtered cell suspension was stained with anti-CD11b-PE (M1/70, BioLegend) and isolated 
following the user manual for anti-PE microbeads (Milteny). 
Co-culture of TCR 3598_2-transduced CD4 T cells and CD11b+ stromal cells was performed 
with 1x105 cells each. 2x105 dynabeads T activator CD3/CD28 or NY-ESO116 peptide were 
added as positive control. IFN was measured in the supernatant by ELISA (BD OptEIA) after 16 





5.1 ABabDR4 mice expressed HLA-DR4 and mounted specific CD4 T cell responses 
First, ABabDR4 mice were analysed for expression of MHC II molecules to confirm expression 
of the transgene HLA-DR4-IE and absence of any murine MHC II molecules. HLA-DR4-IE was 
expressed on B cells from ABabDR4 mice to a similar extent as compared to DR4 mice (Figure 
1A). The intrinsic I-Eb β chain, which does not come to the surface because of the non-functional 
I-Eb α chain in mice with C57BL/6 genetic background, could theoretically bind to HLA-DRA-IE 
(Lawrance et al., 1989). However, as published for the DR4 mice, no I-E was detected above 
background on B cells from ABabDR4 or DR4 mice (Figure 1A; Ito et al., 1996). AKR/J mice, 
which express I-E molecules of the k haplotype, served as a positive control, as the antibody 
binds to both k and b haplotype (Figure 1A). Moreover, absence of the murine MHC II molecule 
I-A was confirmed by surface staining of B cells and blood samples from C57BL/6 and Balb/c 
mice were taken as positive controls for b and d haplotype, respectively (Figure 1A). Finally, 
absence of the functional I-E α chain was confirmed by PCR, showing a shorter band harbouring 
the destructive deletion as for C57BL/6 mice, while the longer band from the intact chain was 
seen for Balb/c mice (Figure 1B).  
To analyse whether ABabDR4 mice can mount a CD4 T cell immune response, they were 
immunized with a Pan-DR binding peptide (Padre), a chemically modified peptide binding to 
most HLA-DR and several mouse MHC II molecules including I-Ab in C57BL/6 mice 
(Alexander et al., 1994). Upon Padre restimulation of spleen and lymph node cells from an 
immunized ABabDR4 mouse, small percentages of CD4 T cells produced IFNγ and/or IL-2 
(Figure 1C). This immune response was similar to the one seen for C57BL/6 mice, while the 
immune response of DR4 mice was smaller. Anti-CD3/CD28 activator beads and an irrelevant 
peptide from NS3 from hepatitis C virus served as positive and negative control, respectively 
(Figure 1C). 
Taken together, ABabDR4 mice expressed exclusively DR4 as MHC II molecule and were able 
to mount a specific immune response. Consequently, ABabDR4 mice may serve as good model 






Figure 1 ABabDR4 mice expressed HLA-DR4-IE and mounted a specific CD4 T cell response. (A) 
Peripheral blood leukocytes from ABabDR4, DR4, AKR/J, C57BL/6 and Balb/c mice were stained for 
HLA-DR and I-Ek/b and/or for I-Ad and I-Ab. Plotted cells were gated on lymphocytes and CD19+ cells. 
(B) Tail DNA from indicated mouse strains were used for PCR with primers that flank a deletion present 
in the non-functional IEb α chain that is present in C57BL/6 but not in Balb/c genetic background. (C) 
Splenocytes from ABabDR4, DR4 and C57BL/6 mice immunized twice with Pan-DR-binding peptide 
(Padre) were pulsed with Padre, anti-CD3/CD28 activator beads or irrelevant peptide (NS3 peptide) and 
were stained intracellularly after overnight incubation. Plotted cells were gated on lymphocytes, CD3 and 




5.2 NY-ESO116-135 was immunogenic and naturally processed in ABabDR4 mice 
To elicit T cell responses against NY-ESO, we immunized ABabDR4 mice with the 20-mer 
peptide NY-ESO116-135 (NY-ESO116), that has been described as immunogenic in a HLA-DR4 
restriction setting (Zeng et al., 2000). As NY-ESO116 has no sequence homology in the mouse, 
the T cell repertoire is not influenced by any tolerance mechanisms (Figure 2A). A distinct CD4 
T cell response to NY-ESO116 but not to an irrelevant peptide (Padre) appeared upon peptide 
restimulation of blood from immunized ABabDR4 mice (Figure 2B, top). To confirm natural 
processing of the NY-ESO116 epitope, ABabDR4 mice were immunized with NY-ESO full length 
DNA. Similarly, CD4 T cells responded specifically to NY-ESO116 (Figure 2B, bottom). To 
expand NY-ESO-reactive CD4 T cells, one-week in vitro cultures of splenocytes were prepared 
in presence of different peptide concentrations. Most efficient expansion of NY-ESO-reactive 
CD4 T cells occurred at a concentration of 10-8 M NY-ESO116, which was applied in further 
expansion cultures (Figure 2C). 
 
5.3 NY-ESO-reactive TCRs were isolated from ABabDR4 mice 
To isolate NY-ESO-reactive TCRs, splenocytes from NY-ESO116 peptide or NY-ESO DNA-
immunized ABabDR4 mice were used. First, NY-ESO-reactive CD4 T cells were labelled by the 
IFNγ capture method and isolated by flow cytometry (Figure 3A). Two predominant TCRα and 
three predominant β chains were identified, which were matched by combinatorial expression 
and subsequent DR4/NY-ESO116 tetramer staining and revealed TCR-3598 and TCR-3598_2 
(Figure 3B). Three subsequent TCR isolations were conducted from DR4/NY-ESO116 tetramer 
stained and sorted cells after one-week in vitro expansion and yielded one predominant TCRα 
and β chain combination each, TCRs 3600, 5712 and 5713 (Figure 3C). As ABabDR4 mice were 
boosted several times, narrowing down the T cell response to few clones that may be of optimal 
affinity is an expected outcome (Savage et al., 1999). 
Of note, all identified TCRβ chains used the TRBV2 gene segment (Figure 4A). To confirm that 
the immune response to NY-ESO116 is dominated by the TRBV2 gene segment, we stained 
peptide-restimulated splenocytes of an immunized ABabDR4 mouse for TRBV2 and IFN. 
Exclusively TRBV2+ CD4 T cells responded to NY-ESO116 (Figure 4B). Human PBLs were 
retrovirally transduced with the TCRs containing mouse constant regions (Cohen et al., 2006) and 




all TCR+ CD4 T cells bound the DR4/NY-ESO116 tetramer. This phenomenon was also 
observed in transduced Jurkat/CD4 cells, that do not express endogenous TCRs (Figure 3B) and 
was therefore not due to formation of mixed TCR dimers composed of endogenous and 
transduced TCR chains but at least partly, to inefficient tetramer binding. Taken together, five 




Figure 2 NY-ESO116-135 was immunogenic and naturally processed in ABabDR4 mice. (A) The amino 
acid sequence of NY-ESO116 and the closest homologous sequence in mice are displayed. (B) Peripheral 
blood leukocytes (PBLs) from an ABabDR4 mouse immunized with NY-ESO116 peptide (upper row) or 
NY-ESO DNA (lower row) were pulsed with NY-ESO116 or Padre as irrelevant peptide and were stained 
intracellularly after overnight incubation. The results shown are representative of >10 (upper row) and 
three (lower row) mice. (C) Splenocytes from an immunized ABabDR4 mouse were cultured one week in 
presence of different concentrations of NY-ESO116 as indicated. Following peptide restimulation, 





Figure 3 Labelling of NY-ESO-reactive CD4 T cells from immunized ABabDR4 mice for TCR 
isolation. (A) NY-ESO116-reactive PBLs were stained for CD4 and labelled by the IFNγ capture method 
following NY-ESO116 restimulation. Cells were gated on lymphocytes, CD3
+ cells and live cells. (B) Two 
TCRα and three TCRβ chains isolated from NY-ESO116-reactive CD4 T cells shown in (A) were 
expressed in different combinations in TCR-deficient Jurkat76/CD4 cells and stained for CD3 and with 
DR4/NY-ESO116 tetramer. (C) NY-ESO116-reactive PBLs were stained by DR4/NY-ESO116 tetramer 
following a one-week culture period in the presence of 10-8 M NY-ESO116 (TCRs 3600 and 5712) or 
αCD3/CD28 beads (TCR-5713). 
5.4 NY-ESO-reactive TCRs were isolated from human CD4 T cells 
To compare the NY-ESO-reactive TCRs derived from ABabDR4 mice with TCRs from human 
individuals, in whom NY-ESO is a self-protein potentially leading to a skewed CD4 T cell 
repertoire, we isolated TCRs from human CD4 T cells. Based on the dominant TRBV2 gene 
segment usage of the NY-ESO-reactive CD4 T cells in ABabDR4 mice (Figure 4), we enriched 
human PBLs from a HLA-DR4+ donor for CD4 T cells expressing TRBV2 and cultured them in 




control. After 2 weeks, more than two percent of the CD4 T cells of two similar in vitro cultures 
stained for DR4/NY-ESO116 tetramer, while this was not the case for the TRBV2 depleted 
fraction (Figure 5A). From both cultures, DR4/NY-ESO116 tetramer+ CD4 T cells were sorted by 
flow cytometry and TCR sequences were isolated. In total, six functional TCRs were identified 
by combinatorial expression of single TCR and  chains and subsequent DR4/NY-ESO116 
tetramer staining (Figure 5B, C). Single chains were considered for combinatorial expression, if 
they occurred at least twice in a total of more than 30 sequenced clones per TCR chain. Five 
TCRs, named NY1-NY5, were chosen for further analyses (Figure 6A). CD4 T cells transduced 
with those TCRs were stained with DR4/NY-ESO116 tetramer (Figure 6B). Thus, human-derived 




Figure 4 NY-ESO-reactive TCRs from ABabDR4 mice. (A) V and J gene segments and CDR3 regions 
of α and β chains of functional TCRs are shown that were isolated from the NY-ESO116-reactive CD4 T 
cells labelled either by the IFNγ capture method (Cap) or by DR4/NY-ESO116 tetramer (Tet) as shown in 
Figure 3. The percentages refer to the frequency in total isolated TCRα or β sequences. (B) Splenocytes 
from an ABabDR4 mouse immunized with NY-ESO DNA were pulsed with Padre as irrelevant peptide or 
NY-ESO116 and stained intracellularly after 6 hours of incubation. Plotted cells were gated on 
lymphocytes, CD3+ and CD4+ and live cells. (C) Human CD4 T cells were transduced with the NY-ESO-
reactive TCRs listed in (A) and stained with DR4/NY-ESO116 tetramer. Plotted cells were gated on 








Figure 5 In vitro expansion of NY-ESO-reactive human CD4 T cells. (A) PBLs from a HLA-DR4+ 
donor were enriched for CD4 T cells expressing the TCRβ variable segment 2 (TRBV2) and cultured in 
the presence of 2 μM NY-ESO116 and irradiated CD4
- cells as feeders. The CD4+ fraction depleted of 
TRBV2+ cells was cultured alike as control. After two weeks, NY-ESO116-reactive cells were stained with 
DR4/NY-ESO116 tetramer and sorted by flow cytometry for isolation of the TCR chains. Two similar in 
vitro cultures are shown (1 and 2). Displayed cells were gated on lymphocytes, live, CD3+ and CD4+ and 
CD8- cells. (B, C) TCRα and β chains isolated from PBL in vitro cultures shown in (A) were expressed in 
different combinations in TCR-deficient 58 cells and stained for CD3 and with DR4/NY-ESO116 tetramer. 




Figure 6 NY-ESO-reactive TCRs from CD4 T cells of a human donor (A) V and J gene segments and 
CDR3 regions of α and β chains of functional TCRs identified by combinatorial expression as shown in 
Figure 5 are listed. TCRs NY1-3 and TCRs NY4-5 were isolated from two similar in vitro cultures. The 
percentages refer to the frequency in the total isolated TCRα or β sequences. (B) Human CD4 T cells were 
transduced with the NY-ESO-reactive TCRs listed in (A) and stained with DR4/NY-ESO116 tetramer. The 
untransduced sample is the same as shown in Figure 4C since experiments in Figure 6B and 4C were 






5.5 ABabDR4-derived TCRs recognized NY-ESO more efficiently than human-derived 
TCRs 
First, the TCRs were tested for function by co-culturing TCR-transduced CD4 T cells with NY-
ESO116-loaded or NY-ESO-transduced cell lines. To enhance MHC II expression, melanoma cell 
lines were pre-treated with IFN, yielding HLA-DR-expression comparable to the untreated LCL 
BSM (Figure 7A). NY-ESO protein expression by the transduced or naturally expressing 
melanoma cell lines was confirmed by Western Blot (Figure 7B). All TCRs recognized the HLA-
DR4+ melanoma cell line FM3 loaded with NY-ESO116 (Figure 7C, left). However, the NY-ESO-
transduced lines FM3 and BSM (both HLA-DR4+) were recognized by all ABabDR4-derived 
TCRs, but not or to a lesser extent by the human-derived TCRs (Figure 7C, right). The 
recognition of the NY-ESO-transduced lines was blocked by HLA-DR antibody, confirming 
HLA-DR4-mediated recognition. Taken together, TCRs from both settings were able to 
recognize loaded NY-ESO116, but ABabDR4-derived TCRs did better in recognizing processed 
NY-ESO in transduced cell lines. 
Next, we sought to determine, whether the NY-ESO-reactive TCRs could recognize naturally 
NY-ESO-expressing melanoma cell lines. To this end we co-cultured TCR-transduced CD4 T 
cells with IFN-pre-treated melanoma cell lines that naturally express NY-ESO and/or HLA-
DR4. Four of five ABabDR4-derived TCRs (3598_2, 3600, 5712, 5713) recognized the NY-ESO 
and HLA-DR4-expressing melanoma cell lines FM56 and FM82, while two of the human-
derived TCRs (NY2 and NY3) recognized, albeit weakly, the melanoma cell line FM56 (Figure 
7D). Again, HLA-DR antibody blocked recognition. As expected, the NY-ESO-negative cell 
line FM3 and the HLA-DR4-negative cell line FM6 were not recognized and addition of 
PMA/Ionomycin elicited IFN secretion in all TCR-transduced CD4 T cells (Figure 7D). 
To further characterize the TCRs, we tested TCR-transduced CD4 T cells in a peptide titration 
assay by co-culturing them with K562/HLA-DR4 cells that were loaded with decreasing amounts 
of NY-ESO119. All ABabDR4-derived and two human-derived TCRs showed recognition up to  
10-10 M, while three human-derived TCRs were less sensitive and showed recognition up to a 
peptide concentration of 10-9 M (Figure 8). ABabDR4-derived TCRs elicited higher maximal 
IFNγ concentrations than the human-derived TCRs. Taken together, ABabDR4-derived TCRs 
recognized more efficiently NY-ESO-transduced cell lines and naturally NY-ESO-expressing 






Figure 7 ABabDR4-derived TCRs recognized NY-ESO+ melanoma cell lines more efficiently than 
human-derived TCRs. (A) Melanoma cell lines pre-treated with IFNγ and the LCL BSM were stained 
for HLA-DR (dark shading) or isotype control (light shading) and measured by flow cytometry. (B) 
Protein lysates from cell lines used for co-culture experiments in (C) and (D) were assessed for presence 
of NY-ESO protein. -Actin was stained as protein loading control. (C, D) TCR-transduced CD4 T cells 
were co-cultured with the LCL BSM (HLA-DR4+) and the melanoma cell lines FM3 (NY-ESO-, HLA-
DR4+), FM6 (NY-ESO+, HLA-DR4-), FM82 and FM56 (both NY-ESO+, HLA-DR4+). Cell lines FM3-NY 
and BSM-NY were transduced to express NY-ESO, BSM-mCh was transduced with mCherry as control. 
NY-ESO116 (NY116), PMA and Ionomycin (P/I) and blocking antibodies αHLA-DR or αHLA-ABC were 
added where indicated. After overnight incubation IFNγ or IL-2 was measured in the supernatant. Mean 
values of intra-assay duplicates with standard deviation are shown. The results are representative of three 





Figure 8 ABabDR4-derived TCRs were more sensitive to NY-ESO than human-derived TCRs. 
TCR-transduced CD4 T cells were co-cultured with K562/DR4 cells loaded with decreasing 
concentrations of NY-ESO119 (NY119). After overnight incubation, IFNγ was measured in the 
supernatant. The data were fitted in three-parameter dose-response curves. The results are representative 
of three independent experiments performed with PBLs from different donors. 
 
5.6 ABabDR4-derived TCR-3598_2 showed no alloreactivity or cross-reactivity  
As in the ABabDR4 mouse only one MHC II allele is present and in the human individual only a 
limited number of MHC alleles, we investigated the NY-ESO-reactive TCRs for potential MHC 
alloreactivity. For this, TCR-transduced CD4 T cells were co-cultured with a panel of 14 LCLs 
expressing different MHC I and II molecules (Appendix 1). The threshold for reactivity was set 
to 500 pg/ml IL-2 in the supernatant, the highest background observed in this assay. Four 
ABabDR4-derived TCRs (TCRs 3598, 3600, 5712, 5713) and one human-derived TCR (TCR-
NY4) reacted to two or more LCL (Figure 9). Which MHC molecule was recognized by the 
cross-reactive TCRs was not further analysed. The ABabDR4-derived TCR 3598_2 did not react 






Figure 9 The ABabDR4-derived TCR-3598_2 showed no alloreactivity. TCR-transduced CD4 T cells were co-cultured with a panel 
of LCLs expressing different MHC class I and II molecules (Appendix 1). As positive control PMA and Ionomycin (P/I) were added to 
the T cells. After overnight incubation IL-2 was measured in the supernatant. Background is indicated by the dotted line. Mean values of 
intra-assay duplicates with standard deviation are shown. In the grid below, cross-reactions to LCLs are summarized. The results are 




For further analysis of potential cross-reactivity, we identified the recognition motifs of the NY-
ESO-reactive TCRs. The 15-mer NY-ESO119 was sequentially mutated to alanine at each position 
and recognition by the TCRs was tested at a concentration of 10-7 M (Figure 10A). In total, nine 
different recognition motifs were identified from the 10 TCRs. While all TCRs required the 
lysine in the 6th position, all but TCR-5713 required the glutamic acid in the 7th position and all 
but TCR-NY5 required the phenylalanine in the 8th position. Of note, there was no clear-cut 
difference in recognition by the ABabDR4-derived and the human-derived TCRs. 
As in the ABabDR4 mouse, TCRs are negatively selected on mouse and not human self-peptides, 
peptides that are not present in the mouse are potentially cross-reactive. As TCR-3598_2 did not 
show alloreactivity in the LCL co-culture, it was further tested with peptides containing its 
recognition motif (X-X-X-X-L-K-E-F-X-X-X-X-X-X-X). Peptides were included if they had a 
predicted IC50 binding affinity to HLA-DR4 of below 500 nM and are present in the human but 
not the mouse proteome (Appendix 2). From the 50 peptides fulfilling these criteria, one peptide, 
X-ray radiation resistance-associated protein 1 (XRRA1)729-743 was recognized by TCR-3598_2 
at 10-6 M but not 10-7 M (Figure 10B). To exclude that this cross-reaction is relevant in a 
physiological setting where XRRA1 must be processed and loaded onto MHC II, TCR-3598_2-
transduced CD4 T cells were co-cultured with full length XRRA1-transduced HLA-DR4+ BSM. 
XRRA1-transduced BSM were recognized only when loaded externally with NY-ESO116 (Figure 
10C). NY-ESO-transduced BSM were recognized as expected. Thus, no relevant cross-reactivity 
of TCR-3598_2 was detected. 
 
5.7 NY-ESO-specific MHC I- and II-restricted TCRs synergize in tumour regression 
To confirm the functionality of TCR-3598_2 in an in vivo setting, we set up a model of ATT in 
which tumour-bearing mice were treated with NY-ESO-specific CD4 and CD8 T cells in 
combination. One month after DR4xRag-/- mice received a subcutaneous injection of 
fibrosarcoma cells (Tet-TagLuc-NY-ESO-HHD clone 1), tumours were palpable and the mice 
were treated with TCR-3598_2-transduced CD4 T cells and CD8 T cells transduced with a TCR 
recognizing NY-ESO157-165 on HLA-A2, named TCR-ESO (Obenaus et al., 2015). Thus, in this 
model CD8 T cells recognize only cancer cells via HHD (HLA-A2-H-2Db chimeric) but not 
cross-presented antigen by tumour stroma cells, while CD4 T cells recognize only cross-





Figure 10 The ABabDR4-derived TCR-3598_2 showed no cross-reactivity. (A) TCR-transduced CD4 
T cells were co-cultured with K562/DR4 cells that were loaded with NY-ESO119 containing single alanine 
exchanges at 10-7 M. After overnight incubation, IFNγ was measured in the supernatant. An amino acid 
was rated as recognition site when the response to the respective alanine exchanged peptide was less than 
one third as compared to the unchanged NY-ESO119-133 at a peptide concentration of 10
-7 M. (B) TCR-
3598_2-transduced CD4 T cells were incubated with K562/DR4 cells loaded with 50 different peptides 
(Appendix 2) containing the recognition motif L-K-E-F. Peptides were included if they had a predicted 
IC50 binding affinity to HLA-DR4 of below 500 nM and are present in the human but not the mouse 
proteome. After overnight incubation IFNγ was measured in the supernatant. (C) TCR-3598_2-transduced 
CD4 T cells were incubated with the HLA-DR4+ BSM transduced to express XRRA1 (XR) or NY-ESO 
(NY). NY-ESO116 was added where indicated. Displayed are IL-2 levels in the supernatant after overnight 
incubation. Mean values of three independent experiments with standard deviation (A) or mean values of 
intra-assay duplicates with standard deviation (B, C) are shown. The results are representative of two 




only present on the host cells. As controls, NY-ESO-specific CD4 or CD8 T cells alone or CD4 
and CD8 T cells expressing an irrelevant TCR were given. In group 1, which received NY-ESO-
specific CD4 T cells alone, tumour growth slowed down, while in group 2, which received NY-
ESO-specific CD8 T cells alone, 4 out of 10 tumours regressed (Figure 11A). In the control 
group 4, which received CD4 T cells transduced with an irrelevant TCR together with NY-ESO-
specific CD8 T cells, 5 out of 8 tumours regressed, while all tumours grew out in the groups 5 
and 6, which received a combination of both irrelevant CD4 and CD8 T cells or no T cells, 
respectively. Only in group 3, which received a combination of NY-ESO-specific CD4 and CD8 
T cells, all tumours (10/10) regressed (Figure 11A). 
Analysis of T cells in peripheral blood of the treated mice revealed a higher number of TCR-
transduced CD8 T cells in group 3, which received NY-ESO-specific CD4 and CD8 T cells in 
combination, compared to all other groups (Figure 11B). Numbers of TCR-transduced CD4 T 
cells were higher in groups 1 and 3, which received TCR-3598_2-transduced CD4 T cells, 
compared to groups 4 and 5, which received irrelevant CD4 T cells (Figure 11B). 
Finally, we analysed cross-presentation of NY-ESO by macrophages to CD4 T cells. To this end 
we co-cultured TCR-3598_2-transduced CD4 T cells with CD11b+ stromal cells purified from a 
control-treated tumour (group 5). The TCR-3598_2-transduced CD4 T cells recognized the 
CD11b+ stromal cells, while this was not the case for untransduced CD4 T cells (Figure 11C). 
Externally loaded NY-ESO116 stimulated abundant IFNγ secretion by TCR-3598_2-transduced 
CD4 T cells and αCD3/CD28-activating beads stimulated IFNγ secretion in the untransduced 
CD4 T cells as well. Thus, in vivo functionality of TCR-3598_2 was confirmed in a mouse model 
of ATT. 
 
5.8 A clinical version of TCR-3598_2 displayed comparable function 
For future clinical application, the fully mouse constant region (mc) of the TCR candidate TCR-
3598_2 was exchanged for a human constant region containing 9 amino acids from the mouse 
sequence referred to as minimally murinized constant region (mmc) (Sommermeyer and Uckert, 
2010). Moreover, additional cysteine bridges were included (Cohen et al., 2007). Surface 
expression   of   TCR-3598_2   mc  and   mmc   were   comparable   with   slightly   higher   mean 
fluorescence intensity for the TCR- 3598_2 mc as judged by v staining of transduced human T 





Figure 11 TCR-3598_2-transduced CD4 T cells in combination with TCR-ESO-transduced CD8 T 
cells caused tumour regression. (A) Tumour-bearing mice were treated with TCR-3598_2-transduced 
CD4 T cells and/or TCR-ESO-transduced CD8 T cells at day 30, when the transplanted tumours were 
palpable. TCR-1367-transduced CD4 and/or CD8 T cells were injected as controls where indicated (CD4-
/CD8-irrelevant). Shown are tumour sizes days after tumour cell injection. (B) Adoptively transferred 
TCR-transduced (Vβ+) CD8 and CD4 T cells were detected in blood 9 days after treatment. Group 
numbers refer to (A). Results from two independent experiments were combined (A, B) t test *P< 0.05, 
**P<0.01. (C) CD11b+ stromal cells isolated from isolated tumour material were recognized by TCR-
3598_2-transduced CD4 T cells. As positive controls, CD11b+ stromal cells were loaded with NY-ESO116 
or anti-CD3/CD28 activator beads were added to the T cells. Mean values of intra-assay duplicates with 









Figure 12 TCR-3598_2 mc and TCR-3598_2 mmc displayed similar functionality. (A) Human CD4 T 
cells were transduced with TCR-3598_2 mc or TCR-3598_2 mmc and stained for CD4, TRBV2 and 
DR4/NY-ESO116 tetramer. Numbers in brackets are mean fluorescence intensity. Plotted cells were gated 
on lymphocytes (top) and CD4+ cells (bottom) (B) TCR-transduced CD4 T cells were co-cultured with 
K562/DR4 cells loaded with decreasing concentrations of NY-ESO119 (NY119). After overnight 
incubation, IFNγ was measured in the supernatant. The data were fitted in three-parameter dose-response 
curves. Mean values of intra-assay duplicates with standard deviation are shown. (C) TCR-transduced 
CD4 T cells were co-cultured with IFNγ-pretreated melanoma cell lines or PMA and Ionomycin (P/I) as 
positive control. After overnight incubation, IFNγ was measured in the supernatant. The results are 







positive as observed previously (Figure 12A, 3B, 4C). To compare functionality of TCR-3598_2 
mc and mmc, peptide sensitivity and recognition of melanoma cell lines were tested. TCR-
3598_2 mc displayed slightly higher peptide sensitivity (Figure 12B). Recognition of NY-ESO-
transduced melanoma cell line FM3 and naturally NY-ESO-expressing melanoma cell lines FM-








In this doctoral thesis, TCRs against NY-ESO were isolated from transgenic mice expressing a 
diverse repertoire of human TCRs as well as from human T cells. We observed a better 
performance of TCRs derived from the mice serving as non-tolerant host compared to TCRs 
derived from a human donor regarding recognition of melanoma cell lines and peptide sensitivity. 
The combined use of a chosen MHC II-restricted TCR candidate from the non-tolerant repertoire 
together with an MHC I-restricted NY-ESO-specific TCR from a non-tolerant repertoire achieved 
tumour regression in a mouse model of ATT. 
 
7.1 Functionality of ABabDR4 mice 
In this study, ABabDR4 mice were taken as source for HLA-DR4-restricted TCRs from a non-
tolerant repertoire of T cells. ABabDR4 mice are a similar model to ABabHHD mice, which were 
generated for TCR isolation from CD8 T cells (Li et al., 2010; Obenaus et al., 2015). While 
ABabHHD mice are transgenic for the mouse/human chimeric MHC I molecule HHD (peptide 
binding site from HLA-A2) and do not express mouse MHC I molecules, ABabDR4 mice are 
transgenic for the mouse/human chimeric HLA-DR4-IE molecule and could be confirmed herein 
not to express any mouse MHC II molecule. Functionality of HLA-DR4-IE has previously been 
shown in DR4 mice by immunization and induction of autoimmune disease in case of 
autoantigens (Ito et al., 1996; Touloukian et al., 2000; Zeng et al., 2000). Ability of ABabDR4 
mice to elicit CD4 T cell responses was shown herein by immunization with Padre and NY-
ESO116, confirming functional CD4 T cell immunity in this model. Thus, ABabDR4 mice are a 
useful tool to isolate human TCRs from a non-human host that can be immunized. 
Although all three mouse strains, ABabDR4, DR4 and C57BL/6 mice, responded to 
immunization with Padre, responses of DR4 mice were smaller. This phenomenon we could 
observe for other HLA-DR4 epitopes as well (Chen et al., 2017). We suggested that an 
incompatibility of the mouse V genes to the human HLA-DR4 accounted for less efficient 
immune responses seen in DR4 mice compared to ABabDR4 mice (Chen et al., 2017). In 
ABabDR4 mice, human TCRs selected on human MHC II showed higher diversity and longer 
CDR3 length in the beta chain compared to ABabHHD mice, in which human TCRs are selected 




TCRs from a non-human host, matching human TCRs with human MHC II as in ABabDR4 mice 
gives rise to a more diverse repertoire of TCRs to isolate from. 
 
7.2 NY-ESO-reactive TCRs from ABabDR4 mice 
7.2.1 Efficiency of immunizations 
Since NY-ESO has no homologue in ABabDR4 mice, they served as non-tolerant repertoire for 
NY-ESO-reactive TCRs. NY-ESO116 peptide immunization was very efficient with only rare 
non-responders but elicited small responses in the range of 1-2% of CD4 T cells. NY-ESO-
responding cells were expanded efficiently in one-week in vitro cultures in presence of the NY-
ESO116 peptide. Interestingly, 10-8 M peptide concentration yielded most IFNγ-secreting cells 
upon peptide restimulation. It can be hypothesized that higher or lower concentrations caused T 
cell exhaustion or inefficient stimulation, respectively. DNA immunization elicited larger 
immune responses after several boosts, however was not efficient leaving many non-responders. 
Together, eliciting anti-NY-ESO CD4 T cell responses by immunization for subsequent TCR 
isolation was well feasible. 
 
7.2.2 Differences in TCR isolation technique 
The NY-ESO-reactive TCRs-3598 and 3598_2 were derived from cells labelled by IFNγ capture 
assay from one single immunized ABabDR4 mouse without prior in vitro expansion. In contrast, 
from DR4/NY-ESO116 tetramer-labelled cells in all three cases only one predominant TCRαβ pair 
was derived. Two of these TCRs (TCR-3600 and TCR-5712) were expanded in the presence of 
low concentration of NY-ESO116, which may be one reason for deriving a monoclonal T cell 
repertoire. However, because DR4/NY-ESO116 tetramer staining of non-cultured T cells failed, 
for the third TCR isolation, T cells were expanded non-specifically by anti-CD3/CD28 activator 
beads, which likewise gave rise to only one predominant TCRαβ pair. Therefore, DR4/NY-
ESO116 tetramer may not bind all NY-ESO116-reactive T cells efficiently. In line with this, TCR-
3598_2 isolated from the IFNγ-labelled T cells binds DR4/NY-ESO116 tetramer only weakly. 
This TCR may have been missed if T cells were labelled by DR4/NY-ESO116 tetramer for TCR 
isolation. Therefore, TCR isolation from IFNγ capture-labelled CD4 T cells may reveal more 




7.2.3 DR4/NY-ESO116 tetramer binding 
Failure of MHC II tetramers to bind all appropriate T cells has been reported in the literature 
(Sabatino et al., 2011; Van Hemelen et al., 2015). The question is, whether TCR functionality 
correlates with tetramer binding. In one study, tetramer-positive and tetramer-negative T cell 
clones showed similar proliferation in response to peptide stimulation (Van Hemelen et al., 
2015). However, peptide was added at high concentration (3 µM) making conclusion regarding 
TCR affinity difficult. On the other side, tetramer-negative T cells have been associated with 
lower affinity TCRs and tetramer staining has been used as correlate for T cell avidity (Falta et 
al., 2005; Sabatino et al., 2011). Nevertheless, TCR-3598_2, which bound only weakly to 
DR4/NY-ESO116 tetramer, showed high peptide sensitivity and recognized melanoma lines 
efficiently. High occurrence of mixed transgenic and endogenous TCRαβ heterodimers could be 
ruled out by inefficient tetramer binding in Jurkat67 cells, which do not express endogenous TCR 
chains (Heemskerk et al., 2003). Thus, DR4/NY-ESO116 tetramer binding intensity cannot be 
taken as direct measure of TCR functionality. 
It must be noted that the DR4/NY-ESO116 tetramer used herein was fully human and not human-
mouse chimeric as the HLA-DR4 molecule in the ABabDR4 mice to enable co-receptor binding 
of murine CD4 while preserving HLA-DR4-restricted antigen-binding. The fully human 
DR4/NY-ESO116 tetramer therefore binds only to the TCR and not the murine CD4 co-receptor. 
Whether this is the decisive factor for inefficient tetramer binding of mouse T cells is 
questionable as CD4 binding to MHC is weak and is believed not to stabilize the TCR-pMHC 
interaction in contrast to CD8 (Wooldridge et al., 2005; Xiong et al., 2001). Apart from the 
tetramer staining for TCR isolation from ABabDR4 mice, human T cells or lines expressing 
human CD4 were stained. 
Of note, TCR-3600 and TCR-5712, both derived from in vitro cultures in presence of NY-ESO116 
peptide, have a very similar β chain with only one amino acid difference and an identical α chain. 
On DNA level, however, CDR3 regions of the α chains were different, so that cross-
contamination during the TCR isolation process can be ruled out. Rather, in vitro culturing in 
presence of NY-ESO116 peptide raised very similar TCRs. Similar functionality of both TCRs 
could also be seen by an identical TCR binding motif, alloreactivity to the same LCLs and similar 





7.2.4 TCR sequence characteristics 
CD4 T cell responses against NY-ESO116 in ABabDR4 mice were dominated by TRBV2 usage. 
As TRBV2 is not overrepresented in the ABabDR4 TCRβ repertoire, TRBV2 seems to play a 
predominant role in NY-ESO116 recognition (Chen et al., 2017). Interestingly, overrepresentation 
of TRBV2 has also been observed for HLA-DR52/NY-ESO119-143 tetramer positive cells from 
NY-ESO vaccinated patients and human PBL in vitro primings (Poli et al., 2013). Although 
HLA-DR52 and HLA-DR4 have 91% homology, it is unclear whether the dominant use of 
TRBV2 for recognition of NY-ESO on both MHC II molecules is due to similar binding of 
CDR2 or 3 regions of TRBV2 to the MHC. Speaking against this, TCR-3598_2 did not recognize 
NY-ESO116 on HLA-DR52 and several other closely homologous HLA-DR molecules (data not 
shown). On the other side, recognition of a similar NY-ESO epitope, NY-ESO119-134, on multiple 
HLA-DR molecules was shown for two T cell clones (Kudela et al., 2007). Thus, only less 
specific TCRs may recognize NY-ESO on multiple MHC molecules due to binding of CDR2 or 3 
regions of the TCR to a homologous region in the MHC II molecules. 
 
7.3 TCRs from human T cells 
7.3.1 TCR sequence characteristics 
Six NY-ESO-reactive TCRs were identified from human T cells of a healthy donor. In the in 
vitro primings, only the TRBV2+ fraction of CD4 T cells expanded. This suggests that dominant 
usage of TRBV2 by NY-ESO116-reactive TCRs, as observed in the ABabDR4 mice, holds true 
for human T cells as well. As the human T cells were not primed by vaccination prior to in vitro 
culture, deriving a polyclonal repertoire of NY-ESO-reactive T cells was expected. Based on the 
conserved usage of TRBV2 of NY-ESO-reactive T cells, chain centricity could be hypothesized, 
in which one TCR chain confers antigen specificity with large tolerance for partner chains. 
However, combinatorial expression of the isolated TCR chains from the in vitro primings did not 
produce any conflicting results concerning TCRαβ pairing. Thus, α and β chains together confer 
specificity to the NY-ESO-reactive TCR without chain centricity of the β chain. Such chain 
centricity can be seen for example in TCRs recognizing the melanocyte differentiation antigen 
MART-126-35 on HLA-A2 (Nakatsugawa et al., 2015; Pinto et al., 2014). These TCRs 
predominantly use TRAV12-2, whose CDR1 and 2 play a dominant role in binding the MART-




Nakatsugawa et al., 2015; Pinto et al., 2014). Thus, TRBV2 dominance was observed for NY-
ESO116-reactive TCRs of human origin, but α chains were not interchangeable, suggesting no 
strong chain centricity of the β chain. 
 
7.3.2 NY-ESO specific CD4 T cell precursors  
The six NY-ESO-reactive TCRs isolated herein were derived from two in vitro primings from 
human T cells from the same blood sample. Nevertheless, TCR sequences derived from both 
cultures did not overlap, suggesting that the expanded T cell clones grew from single precursors. 
Calculating from the starting number of CD4 T cells and identified TCRs, the precursor 
frequency of NY-ESO116-reactive T cells can be estimated to at least 0.6 in 1x106 CD4 T cells. It 
can be assumed that the real frequency is higher, as only well expanded clones were identified by 
the TCR isolation procedure used herein. CD4 T cell precursors with specificity to self or non-
self were reported to range between 1 and 10 in 1x106 CD4 T cells (Su et al., 2013). CD4 T cell 
precursor frequency with specificity for a similar NY-ESO epitope presented on HLA-
DRA/DRB1*0302 was estimated to 10 in 1x106 (Poli et al., 2013). 
 
7.4 CD4 T cell tolerance to NY-ESO 
The results showing better performance of the MHC II-restricted TCRs from the non-tolerant 
repertoire extend a finding in a similar mouse model transgenic for the human TCR gene loci and 
HLA-A2 (ABabHHD mice), in which we have shown that a TCR raised against the HLA-A2 
epitope NY-ESO157-165 is of higher functional activity than 1G4, a TCR obtained from a 
melanoma patient (Obenaus et al., 2015). 
It is important to note that CD4 T cell tolerance as well as immunity has been observed for 
different self-antigens in mouse models. While the CD4 T cell repertoire against 
carcinoembryonic antigen (CEA) was shown to be tolerant, this was not the case for the CD4 T 
cell repertoire against p53 (Bos et al., 2005; Lauwen et al., 2008). Abundance of the antigen and 
availability for MHC II presentation might explain why the uniformly expressed but tightly 
regulated p53 does not lead to tolerance formation, while this is the case for the transgenic 
protein CEA, which was also shown to be expressed in the thymus (Lauwen et al., 2008). Using 
Cre-recombinase as an artificial tissue-restricted self-antigen, it was shown that CD4 T cell 




this study, however, no cre-expression was detected in the thymus. As NY-ESO expression has 
been detected in the thymus (Gotter et al., 2004), a likely outcome is tolerance formation, which 
is supported by our data herein. 
NY-ESO116-reactive CD4 T cells from a human donor were expanded in vitro in presence of NY-
ESO116 peptide. Prompt expansion of NY-ESO-reactive CD4 T cells in culture was also observed 
in other reports and is in line with occasionally observed anti-NY-ESO IgG and CD4 T cell 
responses in cancer patients (Gnjatic et al., 2003; Poli et al., 2013; Wada et al., 2014). Lower 
functional activity of the NY-ESO116-reactive TCRs isolated from the human PBL herein 
suggests that CD4 T cell tolerance to NY-ESO is present in humans and that remaining CD4 T 
cells are of lower avidity. Considering CD8 and CD4 T cell tolerance to NY-ESO, it is not 
surprising that immune responses occurring naturally or evoked by vaccination did not lead to 
sustained clinical success (Fourcade et al., 2014; Takeoka et al., 2017).  
 
7.5 Recognition of melanoma lines 
ABabDR4-derived TCRs recognized HLA-DR4/NY-ESO+ melanoma cell lines. Presentation of 
endogenous antigens does not comply with the classical antigen presentation pathway in which 
exogenous antigens are endocytosed and loaded onto MHC II but can occur through a process 
termed macroautophagy (Schmid et al., 2007). However, it is unclear how relevant 
macroautophagy for antigen presentation on MHC II is for cancer cells, which are not 
professional antigen-presenting cells. NY-ESO+ melanoma cell lines have been recognized by 
CD4 T cells in several cases (Fonteneau et al., 2016; Matsuzaki et al., 2015; Zhao et al., 2006). 
However, tumour recognition was either very weak (Zhao et al., 2006) or antigen processing was 
shown to occur in an unexpected way by intercellular antigen transfer of the melanoma cells and 
hence according to the classical MHC II processing pathway or by using the MHC I processing 
machinery for loading of a 10-mer peptide on HLA-DP4 (Fonteneau et al., 2016; Matsuzaki et 
al., 2014). Melanoma cell lines used herein were pre-treated with IFNγ, which in addition to 
upregulating MHC II on the surface can also enhance the MHC II processing machinery. By 
which mechanism antigen processing occurred was not object of investigation. In general, to 
which extent direct recognition of cancer cells by CD4 T cells plays a role for tumour rejection is 
uncertain as MHC II-negative tumour cells can be rejected by CD4 T cells in mouse models 




7.6 Alternative approaches to isolate TCRs against tumour-associated antigens 
In the case of tumour-associated antigens, which are self-antigens, T cell tolerance can be 
expected as observed for NY-ESO herein. To derive TCRs of higher affinity, which cannot be 
found in the autologous repertoire, several alternative approaches have been used. 
 
7.6.1 HLA-transgenic mice 
HLA-transgenic mice can be immunized with human tumour-antigens, which are not 
homologous in the mouse to derive higher affinity TCRs from responding T cells (Johnson et al., 
2009; Parkhurst et al., 2009). However, the resulting TCRs are fully murine, which bears the risk 
of immunogenicity and consequently low half-life of the infused T cells expressing the TCR in 
the patient (Davis et al., 2010). Moreover, incompatibility of murine V genes and human MHC in 
the HLA-transgenic mice may lead to adjustment to shorter CDR3 regions of the TCRs, 
increasing the risk of cross-reactivity (Gavin and Bevan, 1995; Huseby et al., 2008). Therefore, 
isolating TCRs from mice that do not only express human HLA molecules but also the human 
TCRαβ loci as described herein may be superior. 
 
7.6.2 Affinity maturation 
To increase the affinity of TCRs isolated from the autologous human repertoire, artificial affinity 
maturation has been applied (Linette et al., 2013; Morgan et al., 2013; Robbins et al., 2008). 
However, by circumventing negative selection physiologically taking place in the thymus, cross-
reactivity of the generated TCRs is a risk. Two MAGE-A3-reactive TCRs with enhanced 
affinities led to fatal toxicities in clinical trials due to cross-reactivity (Linette et al., 2013; 
Morgan et al., 2013). Therefore, a method that allows thymic selection as by isolating TCRs from 
humanized mice herein presumably keeps the risk of cross-reactivity lower. 
 
7.6.3 TCRs from T regulatory cells 
In other reports, MHC II-restricted TCRs were isolated from human Tregs thereby avoiding the 
repertoire hole that may have been imposed by tolerance (Yao et al., 2016). In the human T cell 
primings herein, Tregs were not depleted. However, expansion of Tregs is unlikely under the 
given culture conditions including low IL-2. We cannot exclude that high-affinity TCRs against 
NY-ESO can be isolated from human Tregs, as CD4 T cells recognizing self-antigens can 




advantage of the ABabDR4 mouse as TCR source is the natural selection for the fittest 
clonotypes upon repeated immunizations with sufficient long intervals, thus generating highly 
functional TCRs presumably of optimal affinity. 
 
7.6.4 Allogeneic T cell primings 
Another alternative approach to circumvent the problem of T cell tolerance to self-antigens is to 
prime T cells in an alloreactive setting, in which the MHC molecule presenting the tumour 
antigen is non-self (Kumari et al., 2014; Wilde et al., 2012). T cells recognizing tumour antigens 
on non-self MHC molecules are not deleted in the thymus by negative selection and may be a 
source of high-affinity TCRs. However, a drawback is the high proportion of primed T cells that 
recognize the MHC molecule independent of the presented peptide. Although TCRs can be 
analysed for cross-reactivity, decreased specificity may be a general problem of TCRs generated 
by alloreactive primings and may not always be detected. 
 
7.7 Off-target toxicity of isolated TCRs 
7.7.1 Alloreactivity 
Several NY-ESO TCRs isolated from mouse or human in the present study showed alloreactivity 
towards one or more LCLs. Since the TCRs originate from individuals that bear only a limited 
number of MHC molecules and it has been shown that up to 10% of T cells from a naive 
polyclonal repertoire are alloreactive, this finding is plausible but underscores the need for 
thorough alloreactivity testing (Suchin et al., 2001). The presence of more MHC molecules in the 
thymus is thought to lead to a higher number of T cells affected by negative selection and thereby 
less alloreactive T cells (Ni et al., 2014). Hence, the reason for more alloreactive ABabDR4-
derived TCRs in comparison to human-derived TCRs in this study may be that ABabDR4 mice 
express only one MHC II molecule. However, HLA-A2-restricted TCRs generated in ABabHHD 
mice against several antigens including MAGE-A1 and NY-ESO, did not show frequent 
alloreactivity, although these mice express only one MHC I (Obenaus et al., 2015 and 
unpublished data). Whether the frequent alloreactivity in TCRs isolated from ABabDR4 mice is a 
feature found primarily in MHC II-restricted TCRs or related to the NY-ESO specificity will 
become clear when further TCRs against different antigens will be isolated from ABabDR4 mice. 




from a (partly) HLA-mismatched donor, as seen herein by the alloreactivity of one human-
derived TCR against NY-ESO. 
 
7.7.2 Cross-reactivity 
The chosen TCR candidate for clinical application, TCR-3598_2, was analysed for cross-
reactivity by testing epitopes present in the human but not mouse proteome containing its 
recognition motif as identified by alanine scan. One peptide was found to be recognized, but only 
at high concentration. Further analysis revealed this recognition to be irrelevant, because the 
epitope was not processed and presented. The relevance of cross-reactivity analysis by alanine 
scan was tragically exemplified by a clinical trial targeting MAGE-A3 by a patient-derived and 
affinity-matured TCR, in which cross-reactivity to an unrelated protein caused fatal cardiac 
toxicity (Linette et al., 2013). The cross-reactive epitope from the protein titin was later detected 
by alanine scan revealing that the epitope contained the TCR recognition motif (Cameron et al., 
2013). In a recent report, however, cross-reactivity of a TCR against the minor histocompatibility 
antigen HA-2 was only found by a scanning approach using a combinatorial peptide library, in 
which 180 peptide pools are applied to test all possible amino acid combinations (Bijen et al., 
2018). The cross-reactive peptide differed in 5 amino acid positions and could not be detected by 
alanine scan. Therefore, although more laborious, scanning with a combinatorial peptide library 
should be applied in the future to identify cross-reactive TCRs best possible. 
 
7.8 Mouse model of ATT 
7.8.1 Synergy of CD4 and CD8 T cells 
ABabDR4-derived TCR-3598_2-transduced CD4 T cells in combination with TCR-ESO-
transduced CD8 T cells caused regression of palpable tumours in a mouse model of ATT. The 
combined treatment was more effective than treatment with CD4 or CD8 T cells alone. 
Therefore, their synergistic effect was necessary to achieve efficient tumour regression and the in 
vivo functionality of the herein isolated TCR-3598_2 was confirmed. 
Synergy of CD4 and CD8 T cell lines with specificity for NY-ESO has been shown to delay 
tumour growth in a xenograft mouse model (Matsuzaki et al., 2015). In this model, the CD4 T 
cells see an 8-9-mer peptide that is presented on MHC II of the xenografted cancer cells, but 




Matsuzaki et al., 2015). However, recognition of cross-presented antigen was shown to be crucial 
for tumour rejection and required for bystander elimination of antigen-negative cancer cells 
(Schietinger et al., 2010; Spiotto et al., 2004). Therefore, improved recognition of cross-presented 
antigen may be one feature of CD4 and CD8 T cell synergy. TCR-3598_2-transduced CD4 T 
cells recognized re-isolated tumour stromal cells, showing that specific recognition of cross-
presented antigen was implicated in the anti-tumour effect of the CD4 T cells in the model used 
herein. Synergy of CD4 and CD8 T cells with specificity for model antigens has been shown in 
several models (Arina et al., 2017; Bos and Sherman, 2010; Li et al., 2017; Schietinger et al., 
2010). It has become apparent that CD4 T cells, to synergize with CD8 T cells, must be specific 
and act locally at the tumour site, because non-specific CD4 T cells that gave help to CD8 T cells 
only during priming did not improve the outcome (Bos and Sherman, 2010; Schietinger et al., 
2010). Local activity at the tumour site of the specific CD4 T cells in the tumour model used 
herein can be assumed as they recognized re-isolated tumour stromal cells. Moreover, CD8 T cell 
numbers in the blood were higher in the group that received the combined treatment of CD4 and 
CD8 T cells. Therefore, CD4 T cells also induced proliferation and/or survival of the CD8 T 
cells. 
 
7.8.2 Efficacy of CD4 or CD8 T cells alone 
Transfer of NY-ESO-specific CD4 T cells alone delayed tumour growth but did not lead to 
tumour regression. Most in vivo models in which CD4 T cells alone can eradicate transplanted 
tumours either involve very early treatment on day 0 or 1 following tumour injection (Mumberg 
et al., 1999; Perez-Diez et al., 2007) or treatment in conjunction with chemotherapy 5 days after 
tumour injection (Greenberg et al., 1981). In one model, CD4 T cells can reject large B16 
tumours, however only if treated with radiotherapy and anti-CTLA-4 or Th17-differentiation of 
the CD4 T cells prior to infusion (Muranski et al., 2008; Quezada et al., 2010). Following the 
transduction protocol for CD4 T cells used herein, it can be assumed that CD4 T cells have a Th1 
phenotype, which is supported by their ability to secrete IFNγ upon stimulation with CD11b+ 
stromal cells. It would be interesting to investigate, whether Th17 differentiation of the CD4 T 
cells together with tumour irradiation improves the outcome in the model used herein, in which 
the antigen is seen only by cross-presentation and not on the cancer cells. Together, failure to 
reject tumours by CD4 T cells alone was not surprising, as tumours established for one month 




Transfer of NY-ESO-specific CD8 T cells alone or with irrelevant CD4 T cells caused tumour 
regression only in part of the mice. Although CD8 T cells have been shown to reject even large 
established tumours, this was the case when the target was a strong model antigen or when the 
target was overexpressed as trimer minigene (Anders et al., 2011; Leisegang et al., 2016b; 
Schreiber et al., 2012). The Tet-TagLuc cells used in the present study were engineered to 
express the target antigen NY-ESO as full-length protein, which resembles more the physiologic 
situation than a trimer minigene. Moreover, in this model CD8 T cells cannot recognize cross-
presented antigen on stromal cells because of absence of HLA-A2 in the host mice. Insufficient 
rejection by CD8 T cells alone was therefore not unexpected. 
 
7.8.3 Limitations of the model 
Although NY-ESO-specific CD4 and CD8 T cells in combination caused tumour regression 
initially, antigen-negative variants started to outgrow 2-8 weeks following treatment (data not 
shown). Thus, recognition of cross-presented antigen by CD4 T cells in addition to CD8 T cells 
allowed tumour regression in the first place but did not eradicate antigen-loss variants unlike 
other models (Arina et al., 2017; Schietinger et al., 2010). Irradiation or chemotherapy 
concomitantly with ATT may increase the extent of cross-presentation to CD4 T cells thereby 
compensating for the lack of cross-presentation to CD8 T cells and preventing relapse of antigen-
loss variants. 
While the positive results of the mouse model are an indicator for efficacy of the therapy, safety 
cannot be studied in full, because off-target and on-target toxicity may not be comparable to 
humans due to species-specific protein expression. For safety, in vitro assays help to estimate the 
risk of toxicity. 
Although a preclinical mouse model is very useful to evaluate whether a therapy is promising and 
should be tested in patients, it can never exactly reflect the real situation. A clinical trial will 
reveal how successful the developed therapy can be. 
 
7.9 Translation into the clinic 
The NY-ESO-specific TCR-3598_2 derived from the ABabDR4 mouse model showed a 




activity towards NY-ESO, which could be confirmed in an in vivo setting. Therefore TCR-
3598_2 is a promising candidate for clinical application. 
 
7.9.1 Clinical version of TCR-3598_2 
To analyse the isolated NY-ESO-reactive TCRs, they were expressed with murine constant 
regions to increase correct pairing of introduced α and β chains and moreover enable staining of 
TCR expression in human cells by anti-mTCRβ (Cohen et al., 2006). However, immunogenicity 
of the mouse constant regions in a human host may lead to low persistence and consequently low 
efficacy of the TCR-engineered T cells. Antibodies against murine variable regions were 
observed in patients treated with murine TCRs against gp100 or p53 (Davis et al., 2010). 
Therefore, for future clinical application the fully murine constant regions (mc) were exchanged 
for minimally murinized human constant regions (mmc) containing an additional disulphide bond 
to decrease immunogenicity but maintain improved pairing and expression (Cohen et al., 2007; 
Sommermeyer and Uckert, 2010). Both versions of TCR-3598_2, mc and mmc, showed 
comparable functionality with only slightly reduced surface expression and peptide sensitivity of 
TCR-3598_2 mmc. TCR-3598_2 mmc is therefore the version of choice for clinical application. 
 
7.9.2 Clinical application of combined CD4 and CD8 T cells therapy 
Although ATT of solid tumours has achieved objective responses in clinical trials, efficacy must 
be improved, because responses in the majority of patients were short-lived (Rapoport et al., 
2015; Robbins et al., 2015). Low persistence of adoptive T cells and/or outgrowth of antigen-
negative cancer cells, as has been observed in earlier clinical trials, may be prevented by giving 
antigen-specific CD4 T cells in addition to CD8 T cells to induce a more comprehensive anti-
cancer response. The results of the in vivo model herein clearly demonstrated that the 
combination of NY-ESO-specific CD4 and CD8 T cells was more effective than treating with 
CD4 or CD8 T cells only. Therefore, to improve efficacy in ATT, combination of CD4 and CD8 
T cells is a promising approach to test in a first clinical trial. 
Eligible patients for the combined CD4 and CD8 T cell therapy developed herein need to be 
positive for HLA-DR4 and HLA-A2. As the allele frequencies for HLA-DR4 and HLA-A2 are 
approximately 8% and 30%, respectively, only approximately 5% of patients are expected to 
have this haplotype (Schmidt et al., 2009). To be able to recruit enough patients for a clinical 




expressed in a variety of carcinoma entities, however only in a minor fraction of each (Kerkar et 
al., 2016; Park et al., 2016). In contrast, high expression rates were reported in sarcomas with 
76% of synovial sarcoma and >89% of myxoid/round cell liposarcomas with mostly homogenous 
expression pattern of NY-ESO (Hemminger et al., 2013; Lai et al., 2012; Pollack et al., 2012). 
Therefore, synovial sarcoma and myxoid/round cell liposarcoma would be ideal candidates for a 







7-AAD 7-amino-actinomycin D 
ACK Ammonium-chloride-potassium 
APC  Allophycocyanin 
ATT  Adoptive T cell therapy 
AIRE  Autoimmune regulator 
β2m  β2-microglubulin 
CAR  Chimeric antigen receptor 
CD  Cluster of differentiation 
cDNA  Complementary DNA 
CDR  Complementarity determining region 
CEA  Carcinoembryonic antigen 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleoside triphosphate 
EBV  Epstein-Barr virus 
EDTA  Ethylenediaminetetraacetic acid 
ELISA  Enzyme-linked immunosorbent assay 
FCS  Fetal calf serum 
FITC  Fluorescein isothiocyanate 
HLA  Human leucocyte antigen 
HHD  HLA-A2-H-2Db chimeric molecule 
hTCM  Human T cell medium 
IC50  Half maximal inhibitory concentration 
IFNγ  Interferon γ 




IL  Interleukin 
LCL  Lymphoblastoid B cell line 
MACS  Magnetic-activated cell sorting 
MCA  Methylcholanthrene 
MHC  Major histocompatibility 
mTCM Mouse T cell medium 
NS3  Nonstructural protein 3 
Padre  Pan-DR-binding peptide 
PBL  Peripheral blood leukocyte 
PBMC  Peripheral blood mononuclear cells 
PCR  Polymerase chain reaction 
PD-1  Programmed cell death protein 1 
PE  Phycoerythrin 
PBS  Phosphate-buffered saline 
RAG  Recombination-activating gene 
TAP  Transporter associated with antigen processing 
CLIP  Class II-associated invariant chain peptide 
s.c.  Subcutaneously 
SEREX Serological expression cloning 
RACE  Rapid amplification of cDNA ends 
TCR  T cell receptor 
Th  T helper 
TRAV  T cell receptor α variable region 
TRBV   T cell receptor β variable region 
TIL  Tumour infiltrating lymphocyte 
WT  Wild type 
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